Patent Application
20190316180
The present invention relates to methods and systems for labelling nucleic acids and other biological molecules from entities, e.g. cells, within emulsion droplets in high throughput regimes while preserving the integrity of the single-entity information.
Single cell analytics are gaining popularity due to the insight that taking into account the heterogeneity of a population of cell may be of capital interest to understand the function and behaviour of diverse biological systems. Individual cells of a population of clonal unicellular organisms or of multicellular organisms, even among cells of the same tissue or cell-type, often exhibit heterogeneous gene regulation or protein expression patterns. It is thus increasingly recognized that traditional analytical approaches that analyse large populations of cells yield ensemble views that, although informative, only reflect the dominant biological mechanism and fail to identify cell-to-cell variations.
RNA levels are considered a useful marker of phenotypic heterogeneity and, as a consequence, considerable efforts were done to analyse RNA content in single cells. Probe-dependent methods including fluorescence in situ hybridization (FISH) or reporter fusions to fluorescent proteins, was replaced with the probe-independent RNA-seq technique in which cellular RNA molecules are converted into cDNA and subsequently sequenced in parallel using next-generation sequencing technology. Single-cell RNA-seq requires the isolation of individual cells, the conversion of cellular RNA into cDNA and the massively parallel sequencing of cDNA libraries.
The rapid expansion of microfluidic devices has resulted in the development of valve-based microfluidic chips wherein cells are isolated in nano-liter reaction chambers (Streets et al., 2014). However, this approach remains limited not only by the cost but also because the number of single cells that can be currently processed with said chips remains at less than one hundred per run. Alternatively, microfluidic droplets also provide a compartment in which cells can be isolated. Typically, droplets of one phase are generated in another, immiscible phase by exploiting capillary instabilities in a microfluidic two-phase flow. The addition of a surfactant to either or both of the phases stabilizes the droplets against coalescence and allows them to function as discrete microreactors.
Furthermore, as single-cell RNA-seq analysis may require the profiling of several thousands if not millions of representative individual cells, barcoding strategies have been developed to reduce sequencing costs and increase throughput. Using unique cellular identifiers, it has made possible to pool up a multitude of cells for simultaneous sequencing since each read could subsequently be assigned to its original cell through the unique cellular barcode (Islam et al., 2012).
The main technical challenge when combining barcoding strategy and compartmentalization of cells into droplets is to ensure that each droplet carries a different barcode and thus that the integrity of the single cell information is preserved.
Several methods have been described to address this problem. Each cell may be co-encapsulated with a distinctly barcoded particle, such as bead (Macosko et al. 2015) or hydrogel microsphere (Klein et al., 2015), in a nano-liter scale droplet. Each of these particles contains more than 108 individual primers that share the same “cell barcode”. In such a method, in order to ensure that a droplet comprises only one particle, the number of droplets created greatly exceeds the number of particles or cells injected, so that a droplet will generally contain zero or one cell and zero or one particle (Macosko et al. 2015; Klein et al., 2015).
Alternatively, a barcode-library emulsion may be produced using a microfluidic device consisting of 96 drop-makers creating millions of drops containing a high concentration of a single one of the 96 barcodes (Rotem et al. 2015). Each cell-bearing drop is then paired and fused with one barcode-drop. However, to ensure that each cell-bearing drop is fused with at most one barcode drop, only half of the cell-bearing drops actually fuse with a barcode drop. Furthermore, cases where two cell-bearing drops fuse with a single barcode drop or where two barcode drops fuse with a single cell-bearing drop, introduce errors in the resultant labelling and are a potential source of noise (Rotem et al. 2015).
Thus, whatever the method used to ensure that each droplet carries a different barcode, this results in a limited droplet occupancy, a reduced useful fraction of droplets, and thus a reduced throughput.
Furthermore, even if RNA levels have been recognized as useful marker for phenotypic heterogeneity, current methods provide limited information since levels of protein or other biological molecules cannot be assessed with the same system. Indeed, to date, quantification of the protein expression at the single cell level, which is critical for complete characterization of the phenotypic states, is generally based on fluorescence imaging methods.
Consequently, there is a great need for new methods and devices allowing high-throughput quantification of RNA, proteins and other biological molecules of interest at the single entity level.
The present invention provides a new method of labelling any target molecules from a plurality of entities in high throughput regimes while preserving the integrity of the single-entity information.
Accordingly, in a first aspect, the present invention relates to a method of labelling a plurality of molecular targets from a plurality of entities while preserving the integrity of the single-entity information, said method comprising providing a first set of emulsion droplets comprising droplets containing labelled molecular targets, wherein each of these droplets contains a plurality of molecular targets originating from no more than one entity and wherein, in each of these droplets, each molecular target is labelled with a molecular identification DNA sequence comprising (i) a unique molecular identification (UMI) barcode which is different for each molecular target and (ii) an overhang or an overhang producing restriction site;
providing a second set of emulsion droplets comprising droplets containing entity identification sequences, wherein each of these droplets contains at least one entity identification sequence which is a DNA sequence, preferably a double stranded DNA sequence, comprising a unique entity identification (UEI) barcode which is different for each droplet of the second set, and an overhang producing restriction site;
fusing droplets of the first set with droplets of the second set wherein a droplet of the first set is fused with no more than one droplet of the second set; and
ligating UEI barcodes to labelled molecular targets, optionally after restriction enzyme digestion, and
optionally breaking the emulsion.
The method may further comprise
encapsulating a plurality of entities within emulsion droplets, each droplet containing no more than one entity, and optionally lysing said entities within the droplets to release molecular targets;
labelling said molecular targets with probes, each probe comprising
a capture moiety capable of specific binding or ligation to a molecular target or to an adaptor linked to said molecular target, and
a DNA moiety comprising (i) a region proximal to the capture moiety and comprising the unique molecular identification (UMI) sequence and (ii) a region distal from the capture moiety and comprising an overhang or an overhang producing restriction site,
thereby obtaining the first set of emulsion droplets.
The method may further comprise
(i) encapsulating a plurality of entity identification sequences within emulsion droplets, each droplet containing no more than one entity identification sequence, with an amplification reaction mixture, and
amplifying the entity identification sequences within droplets
thereby obtaining the second set of emulsion droplets, or
(ii) encapsulating a plurality of entity identification sequences within emulsion droplets in the presence of UEI-calibrators, wherein at least some droplets comprise one or several entity identification sequences and one or several UEI-calibrators, and wherein said UEI-calibrators are DNA sequences, preferably double stranded DNA sequences, comprising a unique calibrator barcode which is different for each UEI-calibrator and for each droplet, and one or two overhang producing restriction sites; and
amplifying entity identification sequences and/or UEI-calibrators within droplets;
thereby obtaining the second set of emulsion droplets.
Preferably, after fusion of droplets of the first and second sets, (i) UEI calibrator barcodes and UEI barcodes and (ii) UEI barcodes and labelled molecular targets are assembled through restriction enzyme digestion and ligation of compatible overhangs of (i) UEI calibrators and entity identification sequences and of (ii) entity identification sequences and labelled molecular targets.
Alternatively, after fusion of droplets of the first and second sets, (i) UEI calibrator barcodes, UEI barcodes and labelled molecular targets may be assembled through restriction enzyme digestion and ligation of compatible overhangs of (i) UEI calibrators and labelled molecular targets and (ii) UEI calibrators and entity identification sequences, or of i) UEI calibrators and entity identification sequences and (ii) entity identification sequences and labelled molecular targets.
Alternatively, entity identification sequences and UEI-calibrators may be assembled through their compatible overhangs before amplification and, after fusion of droplets of the first and second sets, the amplified fragment comprising UEI calibrator and UEI barcodes is ligated to labelled molecular targets through compatible overhangs of i) UEI calibrators and labelled molecular targets or (ii) entity identification sequences and labelled molecular targets.
Preferably, at least some of molecular targets are nucleic acids and at least some probes comprise
a capture moiety which is a single stranded DNA region which drives the specific recognition of a nucleic acid molecular target through conventional Watson-Crick base-pairing interactions and
a DNA moiety comprising a 3′ single stranded region comprising the unique molecular identification (UMI) sequence and a 5′double-stranded region comprising the overhang or overhang producing restriction site.
Preferably, said nucleic acid molecular targets are labelled using said probes as priming sites for a DNA polymerase synthesizing complementary strands of molecular targets.
In particular embodiments, at least some of molecular targets are RNA molecules and the DNA polymerase is a reverse transcriptase.
In some embodiments, at least some probes comprise a capture moiety which is
(i) a binding moiety that specifically binds to a molecular target and is directly bound to the DNA moiety,
(ii) a chimeric protein comprising a first domain that specifically binds to a molecular target and a second domain that binds to the DNA moiety, or
(iii) a binding moiety that binds specifically to a molecular target and a protein bridge, said protein bridge comprising a first domain that binds to the binding moiety and a second domain that binds to the DNA moiety.
Preferably, (i) the binding moiety or the first domain of the chimeric protein is selected from the group consisting of an antibody, a ligand of a ligand/anti-ligand couple, a peptide aptamer, a nucleic acid aptamer, a protein tag, or a chemical probe (e.g. suicide substrate) reacting specifically with a molecular target or a class of molecular targets, preferably is an antibody, (ii) the first domain of the protein bridge is an immunoglobulin-binding bacterial protein, preferably is domains A to E of protein A, and/or (iii) the second domain of the protein bridge or the chimeric protein is selected from the group consisting of SNAP-tag, CLIP-tag or Halo-Tag, preferably is a SNAP-tag.
In some preferred embodiments, at least some probes comprise a capture moiety comprising an antibody moiety specific to a molecular target and a protein bridge, said protein bridge comprising a first domain that binds to a Fc region of the antibody moiety and a second domain that binds to the DNA moiety, preferably a SNAP-tag.
The present invention also relates to a method of quantifying one or several molecular targets from a plurality of entities with single-entity resolution, said method comprising
labelling said molecular targets according to the method of the invention;
capturing said labelled molecular targets,
amplifying sequences comprising UMI and UEI barcodes, and optionally UEI-calibrator barcodes sequencing amplified sequences.
The sequencing of UMI and UEI barcodes, and optionally UEI-calibrator barcodes, allows to unambiguously assign each molecular target to a droplet/entity and thus to quantify the content of molecular targets in each droplet/entity.
Preferably, the entity is a cell, or a particle or an oil-in-water emulsion droplet exposing molecular targets on its outer surface. More preferably, the entity is a cell.
When the entity is a particle or an emulsion droplet exposing molecular targets on its outer surface, the method may further comprise
thereby obtaining the first set of emulsion droplets.
The present invention further relates to the use of a kit to label a plurality of molecular targets from a plurality of entities according to the method of the invention or to quantify one or several molecular targets from a plurality of entities with single-entity resolution according to the method of the invention, wherein the kit comprises
a microfluidic device comprising
wherein emulsion re-injection modules and/or on-chip droplet generation modules are in fluid communication and upstream to the droplet-pairing module, the droplet-pairing module is in fluid communication and upstream to the module coupling droplet fusion to injection,
and optionally,
Alternatively, the invention relates to the use of a kit to label a plurality of molecular targets from a plurality of entities according to the method of the invention or to quantify one or several molecular targets from a plurality of entities with single-entity resolution according to the method of the invention, wherein the kit comprises
The inventors conceived a new method of labelling any target molecules from a plurality of entities in high throughput regimes, i.e. allowing the analysis of several thousands of entities per run, while preserving the integrity of the single-entity information. This method is based on a tandem molecular barcoding in which all molecular targets (nucleic acids, proteins, . . . ) are labelled (i) with a first unique barcode (unique molecular identification barcode or UMI barcode) which is different for each molecular target from an entity, and (ii) with a tag sequence coding the entity from which the molecular target originates, i.e. unique entity identification barcode or UEI barcode which is different for each entity but identical for all molecular targets originating from the same entity. Once this tandem barcoding is performed, the absolute quantification of all molecular targets with a single-entity resolution may be carried out in a single run of next-generation sequencing making this method highly sensitive and cost-effective.
In a first aspect, the present invention relates to a method of labelling a plurality of molecular targets from a plurality of entities, said method comprising providing a first set of emulsion droplets comprising droplets containing labelled molecular targets, wherein each of these droplets contains a plurality of molecular targets originating from no more than one entity and wherein, in each of these droplets, each molecular target is labelled with a molecular identification DNA sequence comprising (i) a unique molecular identification (UMI) barcode which is different for each molecular target and (ii) an overhang or an overhang producing restriction site;
providing a second set of emulsion droplets comprising droplets containing entity identification sequences, wherein each of these droplets contains at least one entity identification sequence which is a DNA sequence, preferably a double-stranded DNA sequence, comprising a unique entity identification (UEI) barcode which is different for each droplet of the second set, and an overhang producing restriction site;
fusing droplets of the first set with droplets of the second set wherein a droplet of the first set is fused with no more than one droplet of the second set; and
ligating UEI barcodes to labelled molecular targets, optionally after restriction enzyme digestion.
The method of the invention may be used to label molecular targets from any type of entities.
As used herein, the term “entity” refers to any entity comprising or exposing on its surface, molecular targets as defined below. In particular, this term refers to a cell, or refers to a particle or an emulsion droplet, preferably an oil-in-water emulsion droplet, exposing molecular targets on its outer surface.
As used herein, the term “cell” refers to a prokaryotic cell or a eukaryotic cell such as animal, plant, fungal or algae cell. The population of cells to be processed may be homogenous, i.e. comprising only one cellular type, or may be heterogeneous, i.e. comprising several cellular types. In some embodiments, the population of cells is obtained from a tissue sample, preferably an animal tissue sample, more preferably from a pathological sample such as a tumor sample. In some other embodiments, the population of cells is a population of bacterial, fungal or algae cells, preferably of bacterial or fungal cells. This population may comprise bacteria, fungi or algae of the same species or bacteria, fungi or algae of different species.
The terms “particle” and “bead” are used herein interchangeably and refer to any solid support, preferably a spherical solid support, of 50 nm to 10 μm in size which is suitable to expose one or several molecular targets on its outer surface. In particular, these terms may refer to polymer beads (e.g. polyacrylamide, agarose, polystyrene), latex beads, magnetic beads or hydrogel beads. Methods for covalent or non-covalent binding of molecular targets such as nucleic acids or proteins, to beads are well known by the skilled person and various techniques are commercially available. In particular, this binding may be carried out through reactive groups on the surface of the particle. For example, nucleic acids may be attached to the surface by carbodiimide-mediated end-attachment of 5′-phosphate and 5′-NH2 modified nucleic acids to respectively amino and carboxyl beads. Proteins may also be covalently or non-covalently attached to beads via any suitable method such as using sulphate, amidine, carboxyl, carboxyl/sulphate or chloromethyl modified beads.
The term “entity” may also refer to an emulsion droplet, preferably an oil-in-water emulsion droplet, exposing molecular targets on its outer surface. Molecular targets may be covalently or non-covalently attached to the droplet through reactive groups exposed on the surface of the droplets such as nitrilotriacetate which can specifically interact with his-tagged proteins, or through any other functional moiety which is able to covalently or non-covalently interact with a molecular target of interest. The skilled person may use any known method to produce such emulsion droplets exposing molecular targets on its outer surface, in particular methods described in international patent application WO 2017/174610.
The method of the invention allows labelling molecular targets from a high number of entities in a single run. Thus, as used herein, the term “plurality of entities” refers to at least 1,000 entities, preferably at least 5,000 entities, more preferably at least 10,000 entities, and even more preferably at least 50,000 entities.
As used herein, the term “target molecule” or “molecular target” refers to any kind of molecules, and in particular any kind of molecules which may be possibly present in a cell. The molecular target can be a biomolecule, i.e. a molecule that is naturally present in living organisms, or a chemical compound that is not naturally found in living organism such as pharmaceutical drugs, toxicants, heavy metals, pollutants, etc. . . . . Preferably, the molecular target is a biomolecule. Examples of biomolecules include, but are not limited to, nucleic acids, e.g. DNA or RNA molecules, proteins such as antibodies, enzymes or growth factors, lipids such as fatty acids, glycolipids, sterols or glycerolipids, vitamins, hormones, neurotransmitters, and carbohydrates, e.g., mono-, oligo- and polysaccharides. The terms “polypeptide”, “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. The protein may comprise any post-translational modification such as phosphorylation, acetylation, amidation, methylation, glycosylation or lipidation. As used herein, the term “nucleic acid” or “polynucleotide” refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides.
One of the main advantage of the method of the invention, is the possibility to label, in a single run, different types of molecular targets such as proteins and nucleic acids. Thus, the term “plurality of molecular targets” may refer to different copies of the same molecule, e.g. different copies of the same mRNA or of the same protein, or may refer to different copies of different molecules, e.g. different copies of a mRNA and different copies of a protein.
In an embodiment, molecular targets are different copies of the same molecule. Preferably the molecule is biomolecule, more preferably a nucleic acid or a protein, even more preferably a RNA molecule or a protein. In another embodiment, molecular targets are different copies of different molecules. Preferably said molecules are biomolecules, more preferably are nucleic acids and/or proteins, even more preferably RNA molecules and/or proteins. In a particular embodiment, molecular targets are different copies of at least two different nucleic acids, preferably RNA. In another particular embodiment, molecular targets are different copies of at least two different proteins. In a further embodiment, molecular targets are different copies of one or several nucleic acid, preferably RNA, and different copies of one or several proteins.
In preferred embodiments, the method of the invention is implemented using one or several microfluidic systems, i.e. at least one step of the method is implemented using a microfluidic system. In some embodiments, the method is implemented using several microfluidic systems, for example a microfluidic system to generate the first set of emulsion droplets, a microfluidic system to generate the second set of emulsion droplets and a microfluidic system to fuse the two sets, to incorporate UEI barcodes and optionally to conduct some subsequent steps. In some other embodiments, the method is implemented using a microfluidic system wherein the first set of emulsion droplets and/or the second set of emulsion droplets are generated and wherein droplets of the two sets are fused.
As used herein, the terms “emulsion droplet”, “droplet” and “microfluidic droplet” are used interchangeably and may refer to a water-in-oil emulsion droplet (also named w/o droplet), i.e. an isolated portion of an aqueous phase that is completely surrounded by an oil phase, an oil-in-water emulsion droplet (also named o/w droplet), i.e. an isolated portion of an oil phase that is completely surrounded by an aqueous phase, a water-in-oil-in-water emulsion droplet (also named w/o/w droplet) consisting of an aqueous droplet inside an oil droplet, i.e. an aqueous core and an oil shell, surrounded by an aqueous carrier fluid, or an oil-in-water-in-oil emulsion droplet (also named o/w/o droplet) consisting of an oil droplet inside an aqueous droplet, i.e. an oil core and an aqueous shell, surrounded by an oil carrier fluid. Preferably, this term refers to a w/o emulsion droplet.
A droplet may be spherical or of other shapes depending on the external environment. Typically, the droplet has a volume of less than 100 nL, preferably of less than 10 nL, and more preferably of less than 1 nL. For instance, a droplet may have a volume ranging from 2 pL to 1 nL, preferably from 2 to 500 pL, more preferably from 2 to 100 pL. Preferably, the droplets have a homogenous distribution of diameters, i.e., the droplets may have a distribution of diameters such that no more than about 10%, about 5%, about 3%, about 1%, about 0.03%, or about 0.01% of the droplets have an average diameter greater than about 10%, about 5%, about 3%, about 1%, about 0.03%, or about 0.01% of the average diameter of the droplets. Preferably, the emulsion is a monodispersed emulsion, i.e. an emulsion comprising droplets of the same volume. Techniques for producing such a homogenous distribution of diameters are well-known by the skilled person (see for example WO 2004/091763).
The aqueous phase is typically water or an aqueous buffer solution, such as but not limited to Tris-HCl buffer, Tris-acetate buffer, phosphate buffer saline (PBS) or acetate buffer. Preferably, the aqueous phase is an aqueous buffer solution. Optionally, the aqueous phase may comprise bovine serum albumin or additive such as Pluronic. In preferred embodiments, the aqueous phase is chosen in order to be compatible with enzymatic reactions performed during the process of the invention, such as enzymatic digestion, amplification, ligation, etc. . . . . An example of such aqueous phase includes, but is not limited to, CutSmart restriction enzyme buffer (New England Biolabs).
The oil phase used to generate the emulsion droplets may be selected from the group consisting of fluorinated oil such as FC40 oil (3M®), FC43 (3M®), FC77 oil (3M®), FC72 (3M®), FC84 (3M®), FC70 (3M®), Novec-7500 (3M®), Novec-7100 (3M®), perfluorohexane, perfluorooctane, perfluorodecane, Galden-HT135 oil (Solvay Solexis), Galden-HT170 oil (Solvay Solexis), Galden-HT110 oil (Solvay Solexis), Galden-HT90 oil (Solvay Solexis), Galden-HT70 oil (Solvay Solexis), Galden PFPE liquids, Galden® SV Fluids or H-Galden® ZV Fluids; and hydrocarbon oils such as Mineral oils, Light mineral oil, Adepsine oil, Albolene, Cable oil, Baby Oil, Drakeol, Electrical Insulating Oil, Heat-treating oil, Hydraulic oil, Lignite oil, Liquid paraffin, Mineral Seal Oil, Paraffin oil, Petroleum, Technical oil, White oil, Silicone oils or Vegetable oils. Preferably, the oil phase is fluorinated oil such as Novec-7500, FC40 oil, Galden-HT135 oil or FC77 oil, more preferably is Novec-7500. The skilled person may easily select suitable phase oil to implement the methods of the invention.
The emulsion droplets comprise one or several surfactants. Said surfactant(s) can aid in controlling or optimizing droplet size, flow and uniformity and stabilizing aqueous emulsions. Suitable surfactants for preparing the emulsion droplets used in the present invention are typically non-ionic and contain at least one hydrophilic head and one or several lipophilic tails, preferably one (diblock surfactant) or two (triblock surfactant) lipophilic tails. Said hydrophilic head(s) and the tail(s) may be directly linked, or linked via a spacer moiety. Examples of suitable surfactants include, but are not limited to, sorbitan-based carboxylic acid esters such as sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60) and sorbitan monooleate (Span 80); block copolymers of polyethylene glycol and polypropylene glycol such as the triblock copolymer EA-surfactant (RainDance Technologies), DMP (dimorpholino phosphate)-surfactant (Baret, Kleinschmidt, et al., 2009) and Jeffamine-surfactant; polymeric silicon-based surfactants such as Abil EM 90; triton X-100; and fluorinated surfactants such as PFPE-PEG and perfluorinated polyethers (e.g., Krytox-PEG, DuPont Krytox 157 FSL, FSM, and/or ESH). In the context of the invention, preferred surfactants are fluorinated surfactants, i.e. fluorosurfactants.
In some particular embodiments, the emulsion droplets comprise one or several functionalized surfactants at their interface. As used herein, a “functionalized surfactant” refers to a surfactant which bears at least one functional moiety either on one of its hydrophilic head(s) or lipophilic tail(s), preferably on a hydrophilic head. As used herein, a “functional moiety” is virtually any chemical or biological entity which provides the surfactant with a function of interest. For instance, the functional moiety can enable to create a covalent or non covalent interaction between the surfactant and a molecular target of interest. Thanks to the use of such functionalized surfactants, molecular targets may be exposed on the surface of emulsion droplets. The interface of these droplets may comprise only functionalized surfactant(s) or a mix of functionalized and non-functionalized surfactants. The ratio between functionalized and non-functionalized surfactants may vary and can be easily adapted by the skilled person. For example, functionalized surfactant may represent from 1 to 100% (w/w) of total surfactants, preferably from 2 to 80% (w/w), and more preferably from 5 to 50% (w/w).
The total amount of surfactant in the carrier oil is preferably chosen in order to ensure stability of the emulsion and prevent spontaneous coalescence of droplets. Typically, the carrier oil comprises from 0.5 to 10% (w/w), preferably from 1 to 8% (w/w), and more preferably from 2 to 5% (w/w) of surfactant.
The emulsion can be prepared by any method known by the skilled artisan. Preferably, the emulsion can be prepared on a microfluidic system.
Providing the First Set of Emulsion Droplets Comprising Labelled Molecular Targets
The first set of emulsion droplets comprises droplets containing labelled molecular targets, wherein each of these droplets contains a plurality of molecular targets originating from no more than one entity and wherein, in each of these droplets, molecular targets are labelled with a molecular identification DNA sequence.
The first set of emulsion droplets may be a w/o or o/w/o emulsion depending on the nature of the entities. In some embodiments, the entities are cells or particles and emulsion droplets of the first set are w/o emulsion droplets. In some other embodiments, the entities are o/w emulsion droplets exposing molecular targets on their outer surfaces and emulsion droplets of the first set are o/w/o emulsion droplets.
Preferably, the first set of emulsion droplets comprises at least 10,000 droplets, preferably at least 100,000 droplets, preferably at least 500,000 droplets, and even more preferably at least 1,000,000 droplets.
In some embodiments, the first set of emulsion droplets is obtained by
In particular embodiments, entities are particles or o/w emulsion droplets exposing molecular targets on their outer surfaces, and the first set of emulsion droplets is obtained by
In some particular embodiments wherein entities are particles or o/w emulsion droplets exposing molecular targets on their outer surfaces, labelling of molecular targets may be performed in bulk, and then entities attached to labelled molecular targets may be encapsulated.
Thus, when the entity is a particle or an emulsion droplet exposing molecular targets on its outer surface, the method may comprise
In preferred embodiments, entities are cells and the first set of emulsion droplets is obtained by
To ensure single-entity resolution, entities have to be confined and isolated from the beginning to the end of the barcoding process. Encapsulation of entities into microfluidic droplets is a convenient way to isolate said entities and is particularly suitable to high throughput regimes.
Those of ordinary skill in the art is aware of techniques for encapsulating cells or particles within microfluidic droplets (see, for example, the international patent application WO 2004/091763 incorporated herein by reference). If cells are adherent or from tissue, they may be first dissociated and optionally filtered or centrifuged to remove clumps of two or more cells before encapsulation. Cells may typically be suspended in an aqueous buffer such as PBS buffer.
Methods for producing monodisperse w/o/w double emulsions, i.e. for encapsulating o/w droplets are also well known by the skilled person and microfluidic systems generating such emulsions are commercially available.
During encapsulation, the entity number density (entities per unit volume) has to be adjusted to minimize incidences of two or more entities becoming captured in the same droplet. In particular, entities may be encapsulated at a density of less than 1 entity per droplet, preferably at a density of less than 0.2 entity per droplet, in order to prevent co-encapsulation of two or more entities. In preferred embodiments, the entity number density and the average occupancy is adjusted in order to ensure that most, preferably at least 98%, or all of the droplets have only zero or one entity present in them.
Using any well-known microfluidic method to encapsulate entities into microfluidic droplets, entity-bearing droplets may be produced at high frequency, e.g. ranging from 0.5 kHz to 15 kHz, preferably from 1 kHz to 10 kHz, more preferably from 1 kHz to 5 kHz.
In embodiments wherein entities are cells, after encapsulation, cells may be lysed within the droplets in order to release molecular targets. Cell lysis may be performed using any method known by the skilled person such as using physical, chemical or biological means. In particular, cells may be lysed using radiation (e.g. UV, X or y-rays) or laser (see e.g. Rau et al., 2004). The lysis may also be induced by osmotic shock or by addition of a detergent or enzyme (see, e.g. Kintses et al., 2012; Novak et al., 2011; Brown & Audet, 2008). The lysis may also be induced by heat shock.
In some embodiments, the lysis is induced by a lysis agent. Preferably, the lysis agent comprises one or several components altering the osmotic balance, one or several detergents and/or one or several enzymes. More preferably, the lysis agent is Triton X-100, BugBuster® reagent (Merck Millipore), Nonidet P40™ (MP BioMedical), M-PER™ (Thermo Scientific) or B-PER™ (Thermo Scientific).
In an embodiment, the lysis agent is directly added to the aqueous phase of the droplets before encapsulation. In such embodiment, an aqueous stream containing the cells may be combined with a stream of aqueous solution containing the lysis agent just before generation of droplets (see, e.g.
In another embodiment, the lysis agent is introduced inside the droplet after droplet generation by any known technique such as pico-injection or droplet fusion. The emulsion may be then collected and incubated to allow cell lysis.
Typically, the emulsion is incubated from 5 minutes to 1 hour and at a temperature ranging from 4° C. to 25° C. to allow cell lysis.
Alternatively, the lysis may be induced by a heat treatment. Typically, in this case, the emulsion may be incubated from 5 minutes to 1 hour and at a temperature up to 95° C. to allow cell lysis.
The skilled person can easily adapted the incubation temperature during the lysis to the used method.
In some embodiments wherein the w/o interface of the first set droplets comprises functionalized surfactant(s), some or all molecular targets released by cell lysis, may be bound by said surfactant(s) and concentrated onto the inner w/o interface of droplets. Possibly, these w/o droplets can be convert into o/w droplets using droplet inversion as presented in international patent application WO 2017/174610.
In some embodiments wherein entities are particles or o/w emulsion droplets exposing molecular targets on their outer surfaces, molecular targets can be released from said particles or from the surface of said o/w emulsion droplets by the action of a cleaving agent (e.g. restriction enzyme).
Optionally, depending on the nature of molecular targets, one or several additional reagents may be added to the aqueous phase before collection and incubation of the first set emulsion. Examples of such additional reagents may include, but are not limited to DNases, RNases, proteases, protease inhibitors and/or nuclease inhibitors.
In some embodiments, molecular targets are RNA and one or several additional reagents, preferably comprising one or several DNases and/or one or several proteases, are added to the aqueous phase. In some other embodiments, molecular targets are proteins and/or RNA and additional reagents, preferably comprising one or several DNases, are added to the aqueous phase.
Additional reagent(s) and lysis agent may be added simultaneously to the aqueous phase, i.e. directly added to the aqueous phase of the droplets just before encapsulation or after droplet generation by any known technique such as pico-injection or droplet fusion. Alternatively, additional reagent(s) and lysis agent may be added sequentially. In particular, the lysis agent may be added to the aqueous phase before encapsulation by co-flowing a flow of an aqueous solution containing the entities and a flow of a solution containing the lysis agent, and additional reagent(s) may be added after encapsulation, and vice-versa, or the lysis agent and additional reagent(s) may be added sequentially after encapsulation, e.g. separate pico-injection or droplet fusion.
In preferred embodiments, additional reagent(s) and lysis agent are added simultaneously to the aqueous phase, i.e. directly added to the aqueous phase of the droplets just before encapsulation (see, e.g.
After encapsulation, and optionally cell lysis and/or elimination/degradation of some non-targeted molecules, as detailed above, molecular targets are labelled with a molecular identification DNA sequence comprising (i) a unique molecular identification (UMI) barcode which is different for each molecular target and (ii) an overhang or an overhang producing restriction site.
The “UMI sequence” or “UMI barcode” is a randomized nucleotide sequence assigning a unique barcode to each molecular target and thus allows further performing the digital detection/counting of molecular targets initially present into or onto the entity, their absolute quantification and correcting for amplification biases. Indeed, in a droplet, each probe carries a unique identification number (the UMI) and therefore counting the number of different UMI gives the absolute number of labelled molecular targets. Preferably, the UMI sequence is a randomized nucleotide sequence having a length of at least 5 nucleotides, preferably a length from 5 to 15 nucleotides, more preferably a length from 5 to 10 nucleotides. The randomized sequence can be a stretch of contiguous randomized nucleotides or a stretch of semi-randomized nucleotides (i.e. contiguous randomized nucleotides spaced by constant nucleotides). Typical examples of a stretch of semi-randomized nucleotides are stretches where several randomized dinucleotides are spaced by constant dinucleotides, or stretches where several randomized trinucleotides are spaced by constant trinucleotides. Preferably, the UMI sequence is a stretch of semi-randomized nucleotides, in particular a stretch where several randomized dinucleotides are spaced by constant dinucleotides.
An overhang is required to add the UEI barcode and optionally the UEI-calibrator barcode, as detailed below, after fusion with the droplets of the second set. This overhang may be a 3′overhang or a 5′overhang, preferably is a 3′overhang.
The molecular identification DNA sequence may comprise an overhang (3′ or 5′ overhang) compatible with a cohesive end generated by a restriction enzyme, or may comprise an overhang producing restriction site.
In some embodiments, the molecular identification DNA sequence comprises an overhang, preferably a 3′ overhang, compatible with a cohesive end generated by a restriction enzyme. The choice of this configuration ensures that no complementary strand will be synthesized by the filling activity of a polymerase so that the extremity will stay competent for the later UEI addition. In addition, this overhang is compatible with the cleavage product of the restriction enzyme which is used to digest double stranded DNA sequences bearing UEI barcodes or UEI calibrators and comprised in the droplets of the second set as detailed below. Using digestion and ligation, this overhang allows UEI, and optionally UEI-calibrator, addition to each UMI sequence.
In some other embodiments, the molecular identification DNA sequence comprises an overhang producing restriction site, i.e. a restriction site generating a 3′ or 5′overhang, preferably 3′overhang, which is compatible with the cleavage product of the restriction enzyme which is used to digest double stranded DNA sequences bearing UEI barcodes or UEI calibrators and comprised in the droplets of the second set. In a particular embodiment, the overhang producing restriction site on the molecular identification DNA sequence is recognized by the same enzyme than the overhang producing restriction site on double stranded DNA sequences bearing UEI calibrators (see below). In particular, overhangs on labelled molecular targets may be generated while digesting DNA sequences bearing UEI barcodes and DNA sequences bearing UEI calibrators after fusion of droplets of the first and second sets.
Alternatively, in embodiments wherein entities particles or o/w emulsion droplets exposing molecular targets on their outer surfaces, molecular targets may be released from said particles or from the surface of said o/w emulsion droplets by the action of a restriction enzyme, thereby generating a 3′ or 5′overhang. Optionally, the molecular identification DNA sequence may further comprise a type identifier sequence which is a short predefined sequence, preferably having a length from 4 to 8 nucleotides, coding for the nature (e.g. nucleic acid or protein) and/or the identity (e.g. GFP mRNA) of the molecular target. Preferably, the type identifier sequence is proximal to the UMI sequence, more preferably directly adjacent to the UMI sequence.
In preferred embodiments, labelling of molecular targets with UMI barcodes is performed using probes, each probe comprising
a capture moiety capable of specific binding to a molecular target or specific ligation to a molecular target or an adaptor linked to said molecular target and
a DNA moiety comprising the molecular identification DNA sequence, i.e. (i) a region proximal to the capture moiety and comprising the unique molecular identification (UMI) sequence, and optionally a type identifier sequence, and (ii) a region distal from the capture moiety and comprising an overhang, preferably an overhang compatible with a cohesive end generated by a restriction enzyme, or an overhang producing restriction site. Preferably the region distal from the capture moiety comprises a 3′overhang or a 3′overhang producing restriction site.
In embodiments wherein the region distal from the capture moiety comprises a 3′overhang, the 5′end is a phosphorylated 5′end.
Preferably, the restriction site or overhang is separated from the UMI sequence by at least 10 nucleotides, preferably at least 20 nucleotides, and more preferably 20 to 40 nucleotides. Preferably, this separating region has a melting temperature of at least 50° C., more preferably at least 55° C., is GC rich in order to form stable duplexes, does not exhibit any sequence identity with a nucleic acid found in the organism from which the cell is originated and does not contain one of the restriction sites later used for labelling. In preferred embodiments, this region is identical for all probes.
In a particular embodiment, the DNA moiety comprises, from the capture moiety to the restriction site or overhang, a type identifier sequence of 4 to 8 nucleotides, preferably of 4 nucleotides, a UMI sequence of 5 to 15 nucleotides, preferably of 8 nucleotides, and a region of 20 to 40 nucleotides comprising the restriction site or overhang.
The nature of the capture moiety and the structure of the DNA moiety may differ according to type and/or the chemical structure of molecular targets. Since molecular targets of different types and/or chemical structures may be labelled simultaneously, probes contained in the same droplet may have different structures.
In some embodiments, at least some of molecular targets are nucleic acids and at least some probes specific of said nucleic acids are DNA probes comprising
a capture moiety which is a single stranded DNA region which drives the specific recognition of a nucleic acid molecular target, or the specific recognition of a nucleic acid adaptor linked to said molecular target, through conventional Watson-Crick base-pairing interactions, and
a DNA moiety comprising (i) a 3′ single stranded region proximal to the capture moiety and comprising the unique molecular identification (UMI) sequence, and optionally a type identifier sequence, and (ii) a 5′double-stranded region distal from the capture moiety and comprising an overhang, preferably an overhang compatible with a cohesive end generated by a restriction enzyme, or an overhang producing restriction site.
Preferably, the DNA moiety comprises (i) a 3′ single stranded region proximal to the capture moiety and comprising the unique molecular identification (UMI) sequence, and optionally a type identifier sequence, and (ii) a 5′ double-stranded region distal from the capture moiety and comprising a 3′overhang, preferably compatible with a cohesive end generated by a restriction enzyme.
These DNA probes may be produced by any method known by the skilled person such as chemical synthesis.
An exemplary illustration of such a probe is presented in
In these embodiments, the length of the capture moiety has to be sufficient to allow the specific recognition of the target molecule through hybridization. Preferably, the capture moiety is a single stranded DNA region of at least 8 nucleotide long, preferably of 8 to 25 nucleotide long, more preferably of 10 to 15 nucleotide long.
The melting temperature (Tm) of the perfect hybrid formed upon association of the capture moiety with the molecular target is preferably adjusted (e.g. by modulating the length of the sequence specific to the target nucleic acid) in order to be ranged between 30° C. and 70° C., preferably between 30° C. and 60° C., more preferably between 40° C. and 60° C., and even more preferably between 40° C. and 50° C.
Preferably, the difference between melting temperature (Tm) of all probes specific to nucleic acid molecular targets, is lower than 3° C., more preferably lower than 2° C. and even more preferably lower than 1° C.
The capture moiety may be specific to a particular DNA or RNA or may be complementary to a sequence region common to all RNAs, e.g. the capture moiety may be a poly-T tract which is complementary to the poly-A tails of eukaryotic mRNAs or complementary to a nucleic acid adaptor, preferably a DNA adaptor, added to all RNA, for instance through the action of an RNA ligase.
Thus, in some embodiments, the capture moiety drives the specific recognition of a nucleic acid adaptor linked to the molecular targets of interest, e.g. all RNAs. Such adaptor may be, for example, pre-adenylated oligonucleotides (5′-App oligos) which act as substrates for T4 ligases and thus can be ligated to any RNA molecule. Typically such adaptor may be a single stranded DNA region of at least 8 nucleotide long, preferably of 8 to 25 nucleotide, more preferably of 10 to 15 nucleotide long. An exemplary illustration of such embodiment is presented in
In some other embodiments, at least some of molecular targets are nucleic acids and at least some probes specific of said nucleic acids are DNA probes comprising
a capture moiety which is a single stranded DNA region which is able to ligate to a nucleic acid molecular target, and
a DNA moiety comprising (i) a 5′ single stranded region proximal to the capture moiety and comprising the unique molecular identification (UMI) sequence, and optionally a type identifier sequence, and (ii) a 3′double-stranded region distal from the capture moiety and comprising an overhang, preferably an overhang compatible with a cohesive end generated by a restriction enzyme, or an overhang producing restriction site.
Preferably, the capture moiety is a 5′ single stranded DNA region comprising 5′,5′-adenyl pyrophosphoryl moiety (App) onto its 5′-end. Such moiety may act as substrate for T4 ligases and thus can be ligated to the 3′ end any RNA molecule. In this embodiment, the 5′App extremity of the capture moiety directly interacts with the RNA molecular target and ligates to said target in the presence of T4 ligase. Exemplary illustrations of such embodiment are presented in
These DNA probes may be produced by any method known by the skilled person such as chemical synthesis.
Preferably, the capture moiety is specific to a particular DNA or RNA molecule, more preferably is specific to a particular RNA molecule.
In some embodiments, nucleic acid molecular targets may be labelled using probes as described above, and in particular the capture moiety of said probes, as priming sites for a DNA polymerase synthesizing complementary strands of molecular targets. DNA and/or RNA molecular targets are converted into barcoded complementary DNA (cDNA) upon reverse transcription or other DNA polymerization reaction.
In some embodiments, some molecular targets are RNA molecules and the DNA polymerase is a reverse transcriptase. Upon hybridization of the probe, through its capture moiety, to the targeted RNA or the adaptor, reverse transcription can occur and first strand of complementary DNA (cDNA) can be synthesized, said cDNA comprising the UMI sequence of the DNA moiety of the probe.
It will be recognized that DNA polymerization reaction or reverse transcription requires appropriate conditions, for example the presence of an appropriate buffer and DNA polymerase enzyme, temperatures appropriate for annealing of the probes to targeted RNAs or DNAs and the activity of the enzyme and optionally presence of DTT. These conditions mainly depend on the polymerase and may be adapted according to the supplier guidance.
Preferably, in these embodiments, the method further comprises, after lysis step when necessary,
contacting molecular targets with a labelling mixture comprising said DNA probes as described above, at least one DNA polymerase, a dNTP mix (dATP, dCTP, dGTP, dTTP) and optionally an appropriate buffer, and
converting RNA molecular targets into cDNA comprising a molecular identification DNA sequence (UMI) using polymerization reaction.
Alternatively, or additionally, at least some probes may be chimeric molecules made of synthetic DNA oligonucleotides, i.e. the DNA moiety, covalently associated to a second molecule, i.e. the capture moiety, targeting specifically and with high affinity the target molecule and making possible to specifically label any molecule with a signal amplifiable and readable. These probes may be specific of any type of molecular targets, preferably are specific of protein molecular targets.
The capture moiety of these probes may be
(i) a binding moiety that specifically binds to a molecular target and is directly bound to the DNA moiety,
(ii) a chimeric protein comprising a first domain that specifically binds to a molecular target and a second domain that binds to the DNA moiety, or
(iii) a binding moiety that binds specifically to a molecular target and a protein bridge, said protein bridge comprising a first domain that binds to the binding moiety and a second domain that binds to the DNA moiety.
The term “specifically binding” or “specifically binds” is used herein to indicate that this moiety has the capacity to recognize and interact specifically with the molecular target of interest, while having relatively little detectable reactivity with other structures present in the aqueous phase such as other molecular targets that can be recognized by other probes. There is commonly a low degree of affinity between any two molecules due to non-covalent forces such as electrostatic forces, hydrogen bonds, Van der Waals forces and hydrophobic forces, which is not restricted to a particular site on the molecules, and is largely independent of the identity of the molecules. This low degree of affinity can result in non-specific binding. By contrast when two molecules bind specifically, the degree of affinity is much greater than such non-specific binding interactions. In specific binding a particular site on each molecule interacts, the particular sites being structurally complementary, with the result that the capacity to form non-covalent bonds is increased. Specificity can be relatively determined by binding or competitive assays, using e.g., Biacore instruments. The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). In preferred embodiments, the Kd representing the affinity between the capture moiety and the molecular target of interest is from 1·10−7M or lower, preferably from 1·10−8M or lower, and even more preferably from 1·10−9M or lower.
In some embodiments, at least some probes comprise a capture moiety which is a binding moiety that specifically binds to a molecular target and is directly bound to the DNA moiety. Preferably the binding moiety is covalently bound to the DNA moiety.
Examples of binding moieties include, but are not limited to, antibodies, ligands of ligand/anti-ligand couples, peptide and nucleic acid aptamers, protein tags, or chemical probes (e.g. suicide substrate) reacting specifically with a molecular target or a class of molecular targets.
Examples of ligand/anti-ligand couples include, but are not limited to, antibody/antigen or ligand/receptor. In particular, in some embodiments, the molecular target is an antibody and the binding moiety is an antigen recognized by said antibody, or vice-versa. In some other embodiments, the molecular target is a receptor and the binding moiety is a ligand recognized by said receptor, or vice-versa.
A multitude of protein tags are well-known by the skilled person (see for example Young et al. Biotechnol. J. 2012, 7, 620-634) and may be used in the present invention. Examples of such protein tags include, but are not limited to, biotin (for binding to streptavidin or avidin derivatives), glutathione (for binding to proteins or other substances linked to glutathione-S-transferase), lectins (for binding to sugar moieties), c-myc tag, hemaglutinin antigen (HA) tag, thioredoxin tag, FLAG tag, polyArg tag, polyHis tag, Strep-tag, OmpA signal sequence tag, calmodulin-binding peptide, chitin-binding domain, cellulose-binding domain, S-tag, and Softag3, and the like.
A multitude of chemical probes are well-known by the skilled person (see for example Niphakis and Cravatt, Ann. Rev. of Biochem. 2014, 83, 341-77 and Willems et al. Bioconjugate Chem. 2014, 25, 1181-91) and may be used in the present invention. Examples of chemical probes include, but are not limited to, electrophile or photoreactive Activity-Based Probes (ABP), suicide substrate-based ABP and inhibitors-based ABP.
In a particular embodiment, at least some probes are aptamer-based probes, i.e. probes comprising a nucleic acid or peptide aptamer as capture moiety. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure. Aptamers can specifically recognize a wide range of targets, such as proteins, nucleic acids, ions or small molecules such as drugs and toxins.
Peptides aptamers consist of a short variable peptide loop attached at both ends to a protein scaffold such as the bacterial protein thioredoxin-A. Typically, the variable loop length is composed of ten to twenty amino acids. Peptide aptamer specific of a target of interest may be selected using any method known by the skilled person such as the yeast two-hybrid system or Phage Display. Peptides aptamers may be produced by any method known by the skilled person such as chemical synthesis or production in a recombinant bacterium followed by purification.
Preferably, at least some probes comprise a nucleic acid aptamer as capture moiety. Nucleic acid aptamers are a class of small nucleic acid ligands that are composed of RNA or single-stranded DNA oligonucleotides and have high specificity and affinity for their targets. Systematic Evolution of Ligands by EXponential enrichment (SELEX) technology to develop nucleic acid aptamers specific of a target of interest, is well known by the skilled person and may be used to obtain aptamers specific of a particular molecular target. Nucleic acid aptamers may be produced by any method known by the skilled person such as chemical synthesis or in vitro transcription for RNA aptamers. Preferably, nucleic acid aptamers used as capture moiety are selected from the group consisting of DNA aptamers, RNA aptamers, XNA aptamers (nucleic acid aptamer comprising xeno nucleotides) and spiegelmers (which are composed entirely of an unnatural L-ribonucleic acid backbone). An exemplary illustration of such a probe is presented in
In another particular embodiment, at least some probes are antibody-based probes, i.e. probes comprising an antibody as capture moiety.
The term “antibody” herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, antibody fragments, and derivatives thereof, so long as they specifically bind to the molecular target of interest. In particular, the antibody may be a full length monoclonal or polyclonal antibody, preferably a full length monoclonal antibody. Preferably, this term refers to an antibody with heavy chains that contain an Fc region. By “Fc”, “Fc fragment” or “Fc region”, used herein is meant the polypeptide comprising the constant region of an antibody excluding the first constant region immunoglobulin domain. Thus Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains. Preferably, the antibody is a full length monoclonal or polyclonal IgG antibody, preferably a full length monoclonal IgG antibody. A large number of specific and high affinity monoclonal antibodies are currently available on the market.
As used herein, the term “antibody fragment” refers to a protein comprising a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab′, F(ab)2, F(ab′)2, F(ab)3, Fv (typically the VL and VH domains of a single arm of an antibody), single-chain Fv (ScFv), dsFv, Fd (typically the VH and CH1 domains) and dAb (typically a VH domain) fragments, nanobodies, minibodies, diabodies, triabodies, tetrabodies, kappa bodies, linear antibodies, and other antibody fragments that retain antigen-binding function (e.g. Holliger and Hudson, Nat Biotechnol. 2005 September; 23(9):1126-36). Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of intact antibody as well as recombinant host cells (e.g. E. coli or phage). These techniques are well-known by the skilled person and are extensively described in the literature. Preferably, the antibody fragment is selected from the group consisting of Fab′, F(ab)2, F(ab′)2, F(ab)3, Fv, single-chain Fv (ScFv) fragments and nanobodies.
The term “antibody derivative”, as used herein, refers to an antibody provided herein, e.g. a full-length antibody or a fragment of an antibody, wherein one or more of the amino acids are chemically modified, e.g. by alkylation, PEGylation, acylation, ester or amide formation or the like. In particular, this term may refer to an antibody provided herein that is further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
In some embodiments, the capture moiety is selected from the group consisting of monoclonal and polyclonal antibodies, Fab′, F(ab)2, F(ab′)2, F(ab)3, Fv, single-chain Fv (ScFv) fragments and nanobodies, and derivatives thereof. In some preferred embodiments, the capture moiety is selected from the group consisting of a monoclonal antibody, a ScFv fragment or a nanobody.
In some embodiments, at least some probes comprise a capture moiety which is a chimeric protein comprising a first domain that specifically binds to a single molecular target and a second domain that binds to a single DNA moiety. Preferably the second domain is covalently bound to the DNA moiety.
The first domain of the chimeric protein specifically binds to a single molecular target. Examples of first domains include, but are not limited to, antibodies, ligands of ligand/anti-ligand couples, peptide and nucleic acid aptamers, protein tags, and chemical probes, as described above. Preferably, the first domain of the chimeric protein is selected from the group consisting of antibodies and peptide aptamers, more preferably is a monoclonal antibody.
In a particular embodiment, the first domain of the chimeric protein is an antibody, preferably selected from the group consisting of monoclonal and polyclonal antibodies, Fab′, F(ab)2, F(ab′)2, F(ab)3, Fv, single-chain Fv (ScFv) fragments and nanobodies, and derivatives thereof. More preferably, the first domain of the chimeric protein is selected from the group consisting of a monoclonal antibody, a ScFv fragment or a nanobody, and even more preferably from the group consisting of a ScFv fragment or a nanobody.
The second domain that covalently binds to the DNA moiety may be any domain allowing covalently grafting of a single nucleic acid. Examples of such domains include, but are not limited to, SNAP-tag® (New England Biolabs), CLIP-tag® (New England Biolabs), Halo-tag® (Promega). Preferably, the second domain is a SNAP-tag®. The SNAP-tag is a 20 kDa mutant of the DNA repair protein O6-alkylguanine-DNA alkyltransferase that reacts specifically and rapidly with benzylguanine (BG) derivatives leading to irreversible covalent association of the SNAP-tag with the DNA moiety attached to BG.
The chimeric protein used as capture moiety and comprising the first and second domains may be produced as fusion protein using any well-known recombinant engineering technology, before to be covalently associated to the DNA moiety of the probe.
In some embodiments, at least some probes comprise a capture moiety comprising (i) a binding moiety that specifically binds to a molecular target and (ii) a protein bridge, said protein bridge comprising a first domain that binds to the binding moiety and a second domain that binds to the DNA moiety. Preferably the second domain is covalently bound to the DNA moiety. The first domain may be covalently or non-covalently bound to the binding moiety, preferably non-covalently bound. In embodiments wherein the first domain non-covalently binds to the binding moiety, the non-covalent interaction is preferably turned into covalent interaction by cross-linking the first domain and the binding moiety.
The second domain of the protein bridge may be as described above for the chimeric protein, i.e. any domain allowing covalently grafting of a single nucleic acid. Preferably, the second domain of the protein bridge is a SNAP-tag®.
The first domain of the protein bridge may be any domain allowing covalent or non-covalent interaction with the binding moiety, preferably non covalent interaction. Examples of such domain includes, but are not limited to, immunoglobulin-binding bacterial proteins such as protein A, protein A/G, protein G and protein L.
In an embodiment, the first domain of the protein bridge is an immunoglobulin-binding bacterial protein and the binding moiety is an antibody, preferably an antibody containing a Fc region, more preferably a full length monoclonal or polyclonal IgG antibody, preferably a full length monoclonal IgG antibody. The immunoglobulin-binding bacterial protein is preferably selected from protein A, protein A/G, protein G and protein L, one or several IgG-binding domains thereof, and functional derivatives thereof.
Protein A is a cell surface protein found in Staphylococcus aureus. It has the property of binding the Fc region of a mammalian antibody, in particular of IgG class antibodies. The amino-terminal region of this protein contains five highly homologous IgG-binding domains (termed E, D, A, B and C), and the carboxy terminal region anchors the protein to the cell wall and membrane. All five IgG-binding domains of protein A bind to IgG via the Fc region and in principle, each of these domains is sufficient for binding to the Fc-portion of an IgG.
Thus, in a particular embodiment, the first domain of the protein bridge is selected from the group consisting of domains A, B, C D and E of protein A, combinations thereof and functional derivatives thereof retaining IgG binding functionality of wild-type protein A. Preferably, the first domain of the protein bridge comprises domains A to E of protein A.
The protein bridge may be produced as fusion protein using any well-known recombinant engineering technology, before to be covalently associated to the DNA moiety of the probe.
Preferably, the first domain is located at the N-terminal part of the protein bridge and the second domain is located at the C-terminal part of the protein bridge.
Optionally, the protein bridge may further comprise at the C-terminal extremity an affinity tag (e.g. a polyhistidine-tag) to facilitate its purification.
In a particular embodiment, the protein bridge comprises an immunoglobulin-binding bacterial protein, preferably domains A to E of protein A, as first domain, a SNAP-tag® as second domain and a monoclonal or polyclonal IgG antibody as binding moiety, preferably a monoclonal IgG antibody. An exemplary illustration of such a probe is presented in
The binding moiety may be covalently or non-covalently bound to the protein bridge. In some embodiments, the protein bridge can be cross-linked with the binding moiety to ensure long-term physical link.
In chimeric probes described above, the DNA moiety consists of a double stranded DNA molecule comprising an overhang, preferably compatible with a cohesive end generated by a restriction enzyme, or an overhang producing restriction site as described above for DNA probes. Preferably, the overhang comprised in the DNA moiety or generated by the restriction site is a 3′overhang. As described above, the DNA moiety comprises a unique molecular identification (UMI) sequence, and optionally a type identifier sequence.
Preferably, in chimeric probes, the DNA moiety further comprises a sequencing primer annealing sequence which is proximal to the capture moiety. After labelling of molecular targets, this sequence allows direct amplification using sequencing primers.
Preferably, in embodiments wherein at least some probes are chimeric probes, the method further comprises, after lysis step when necessary, contacting molecular targets with a labelling mixture comprising at least one chimeric probe.
The labelling mixture comprising probes, and optionally reagents to perform DNA polymerization reaction, may be added to the aqueous phase of the droplets before encapsulation of cells (i.e. by direct inclusion in the mixture or via a co-flow) or after droplet generation by any known technique such as pico-injection or droplet fusion. Preferably, the labelling mixture is added after incubation allowing cell lysis and/or elimination/degradation of some non-targeted molecules.
In a particular embodiment, the labelling mixture is encapsulated into w/o droplets and these droplets are fused with droplets comprising molecular targets. The content of each droplet comprising the labelling mixture should be substantially identical. Methods to produce such emulsion are well known by the skilled person as well as methods of generating, synchronizing and fusing emulsion droplets, in particular on a microfluidic device.
Providing the Second Set of Emulsion Droplets Comprising Cell Identification Sequences
The second set of emulsion droplets comprises droplets containing entity identification sequences, wherein each of these droplets contains at least one entity identification sequence.
The entity identification sequence is a double stranded DNA sequence of 40 to 100 nucleotide long, preferably of 50 to 70 nucleotide long, comprising a unique entity identification (UEI) barcode which is different for each droplet of the second set, and an overhang producing restriction site, preferably a 3′overhang producing restriction site.
The “UEI sequence” or “UEI barcode” is a randomized nucleotide sequence assigning the same barcode to each molecular target originating from the same entity. Preferably, the UEI sequence is a randomized nucleotide sequence having a length of at least 8 nucleotides, preferably a length from 8 to 20 nucleotides, more preferably a length from 8 to 15 nucleotides. The randomized sequence can be a stretch of contiguous randomized nucleotides or a stretch of semi-randomized nucleotides (i.e. contiguous randomized nucleotides spaced by constant nucleotides). Typical examples of a stretch of semi-randomized nucleotides are stretches where several randomized dinucleotides are spaced by constant dinucleotides, or stretches where several randomized trinucleotides are spaced by constant trinucleotides. Preferably, the UEI sequence is a stretch of semi-randomized nucleotides, in particular a stretch where several randomized dinucleotides are spaced by constant dinucleotides.
The restriction site comprised in the entity identification sequence may generate, upon digestion with the corresponding restriction enzyme, an overhang compatible with the overhangs of labelled molecular targets, or an overhang compatible with the overhangs of UEI calibrators as described below, and thus allows addition of UEI sequence to the molecular identification DNA sequence. Preferably, this restriction site is a non-palindromic cleavage site.
Optionally, the entity identification sequence may further comprise a sequencing primer annealing sequence adjacent to the UEI barcode and at the opposite end of the restriction site.
In preferred embodiments, the entity identification sequence comprises a constant region allowing for amplification of the UEI-bearing DNA, adjacent to the restriction site and at the opposite end of the UEI barcode and the sequencing primer annealing sequence when present. Preferably, this constant region has a length of 15 to 35 nucleotides, preferably of 20 to 30 nucleotides. Preferably, this constant region has a melting temperature comprised between 50° C. and 70° C.
An exemplary illustration of such entity identification sequence is presented in
Preferably, all entity identification sequences have to same sequence except for the UEI barcode sequence, i.e. they exhibit the same sequencing primer annealing sequence, the same restriction site and the same constant region.
Whereas the UEI sequence has to be different for each droplet, it also has to be present in large number of identical copies in each droplet.
Thus, in an embodiment, the method further comprises encapsulating a plurality of entity identification sequences within emulsion droplets, each droplet containing no more than one entity identification sequence, with an amplification reaction mixture, and amplifying the entity identification sequences within droplets, thereby obtaining the second set of emulsion droplets. This way, more than one million of copies of the same entity identification sequence can be generated in each droplet and later serve to barcode the previously labeled molecular targets with an identical and unique UEI sequence. Entity identification sequences may be encapsulated in single or double stranded form, preferably in double stranded form.
The amplification reaction mixture comprises all reagents required to perform DNA amplification into the droplets, i.e. typically a DNA polymerase, primers, buffers, dNTPs, salts (e.g. MgCl2), etc. . . . . Primers are designed in order to allow the complete amplification of the entity identification sequence. In certain embodiments, amplification relies on alternating cycles of heating and cooling (i.e., thermal cycling) to achieve successive rounds of replication (e.g., PCR). Methods of amplifying genetic elements compartmentalized in emulsion droplets are well-know and widely practiced by the skilled person (see for example, Chang et al. Lab Chip. 2013 Apr. 7; 13(7):1225-42; Zanoli and Spoto, Biosensors 2013, 3, 18-43). In particular, the amplification may be performed by any known technique such as polymerase chain reaction (PCR), nucleic acid sequence-based amplification (NASBA), loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), rolling circle amplification (RCA), multiple displacement amplification (MDA) and recombinase polymerase amplification (RPA). The suitable method can be easily chosen by the skilled person depending on the nature of the encapsulated genetic element and the molecular target. Preferably, entity identification sequences are amplified into the droplets by PCR amplification.
Preferably, in this embodiment, in order to prevent co-encapsulation of more than one entity identification sequence in one droplet, and thus to preserve single-entity resolution, the DNA solution comprising entity identification sequences is strongly diluted, e.g. in the amplification reaction mixture, such that, according to Poisson statistics driving molecule distribution, droplet occupancy, i.e. the percentage of droplets comprising a entity identification sequence, is limited to less than 20%, preferably to less than 10%. Thus, in particular embodiments, the method further comprises, before encapsulating entity identification sequences and amplification reaction mixture within emulsion droplets, diluting entity identification sequences, preferably into the amplification reaction mixture, in order to obtain a droplet occupancy of less than 20%, preferably less than 10%.
In order to increase droplet occupancy, encapsulation of several entity identification sequence in one droplet may be tolerated. In this case, the inventors found that single-entity resolution can be preserved by adding UEI-calibrator molecules to entity identification sequences. Thus, in a preferred embodiment, the method further comprises encapsulating a plurality of entity identification sequences within emulsion droplets in the presence of UEI-calibrators and an amplification reaction mixture, wherein at least some droplets comprise one or several entity identification sequences and one or several UEI-calibrators; and
amplifying entity identification sequences and/or UEI-calibrators within droplets, preferably entity identification sequences and UEI-calibrators using a multiplex reaction;
thereby obtaining the second set of emulsion droplets.
Entity identification sequences and UEI-calibrators may be encapsulated in single or double stranded form, preferably in double stranded form.
Preferably, for multiplex reaction, a higher amount of primers specific of the entity identification sequences is used relative to those specific for the UEI-calibrators.
The possibility of co-encapsulating several entity identification sequences in the same droplets leads to a dramatic increase of droplet occupancy. Indeed, adjusting the dilution of the entity identification sequence solution in order to co-encapsulate five entity identification sequences per droplets, leads to a droplet occupancy close to 100%.
Preferably, dilutions of entity identification sequence solution and UEI-calibrator solution are adjusted in order to co-encapsulate 2 to 10 entity identification sequences per droplet, preferably 4 to 6 entity identification sequences per droplet, and 2 to 10 UEI-calibrators per droplet, preferably 4 to 6 UEI-calibrators per droplet.
UEI-calibrators are DNA sequences, preferably double stranded DNA sequences, comprising a unique calibrator barcode which is different for each UEI-calibrator and for each droplet, and one or two overhang producing restriction sites, preferably generating overhangs compatible with overhangs of digested entity identification sequences and/or labelled molecular targets.
Preferably, these overhang producing restriction sites are non-palindromic cleavage sites. Preferably, these restriction sites generate 3′ overhangs. Preferably, these restriction sites are different from the restriction site generating compatible overhangs on entity identification sequences and/or the restriction site generating compatible overhangs on labelled molecular targets. The “UEI-calibrator sequence” or “UEI-calibrator barcode” is a randomized nucleotide sequence having a length of at least 15 nucleotides, preferably a length from 15 to 40 nucleotides, more preferably a length from 15 to 20 nucleotides. The randomized sequence can be a stretch of contiguous randomized nucleotides or a stretch of semi-randomized nucleotides (i.e. contiguous randomized nucleotides spaced by constant nucleotides). Typical examples of a stretch of semi-randomized nucleotides are stretches where several randomized dinucleotides are spaced by constant dinucleotides, or stretches where several randomized trinucleotides are spaced by constant trinucleotides. Preferably, the UEI-calibrator barcode is a stretch of semi-randomized nucleotides, in particular a stretch where several randomized dinucleotides are spaced by constant dinucleotides.
In an embodiment, UEI-calibrators comprise an overhang producing restriction site which generates, upon digestion with the corresponding restriction enzyme, an overhang compatible with overhangs of digested entity identification sequences comprising UEI barcodes. In this embodiment, since both types of molecules, i.e. UEI-calibrator sequences and entity identification sequences, carry restriction sites generating compatible extremities, the subsequent digestion/ligation step used for UEI addition to labelled molecular targets, leads to the formation of different chimeras between UEI and UEI-calibrator barcodes. Indeed, whereas a large fraction of UEI barcodes will stay available for the barcoding of the labeled molecular targets originating from the entity, a sub fraction of UEI barcodes will get associated to each of the UEI-calibrator barcodes. These pairs of sequences constitute a signature unique to each droplet and allow reassigning each analyzed molecule to its original entity, despite the presence of multiple entity identification sequences in some droplets (see e.g.
Preferably, in this embodiment, UEI-calibrators comprise a constant region adjacent to the restriction site and at the opposite end of the UEI-calibrator barcode and the sequencing primer annealing sequence when present. This constant region allows amplifying UEI-calibrators, preferably using PCR amplification. In particular, this region may comprise a primer binding site. Preferably, this constant region has a length of 10 to 35 nucleotides, preferably of 15 to 25 nucleotides. Preferably this constant region is orthogonal to that of entity identification sequences in order to prevent unwilling hybridization. UEI-calibrators may further comprise an additional region comprised between the UEI-calibrator barcode and the sequencing primer annealing sequence when present. This region acts as a spacer between the sequencing primer annealing sequence and the UEI-calibrator barcode and may be used to adjust the length of the amplified sequences comprising UEI and UEI-calibrator barcodes to the length of the amplified sequences comprising UMI and UEI barcodes to limit potent amplification biases. An exemplary illustration of such UEI-calibrator is presented in
In another embodiment, UEI-calibrators comprise two overhang producing restriction sites, a first restriction site generating an overhang compatible with overhangs of digested entity identification sequences comprising UEI barcodes and a second restriction site generating an overhang compatible with overhangs of labelled molecular targets. In this embodiment, the subsequent digestion/ligation step used for UEI addition to labelled molecular targets, leads to the formation of tripartite molecules comprising a labelled molecular target, an UEI sequence and a UEI-calibrator barcode (see e.g.
In this embodiment, UEI-calibrators may comprise constant regions adjacent to each of the two overhang producing restriction sites. These constant regions allow amplifying UEI-calibrators, preferably using PCR amplification. In particular, these regions may comprise primer binding sites. Preferably, these constant regions have a length of 10 to 35 nucleotides, preferably of 15 to 25 nucleotides. Preferably these constant regions are orthogonal to that of entity identification sequences in order to prevent unwilling hybridization. An exemplary illustration of such UEI-calibrator is presented in
Preferably, all UEI-calibrators have to same sequence except for the UEI-calibrator barcode sequence, i.e. they exhibit, the same restriction site, the same constant region(s) and optionally the same sequencing primer annealing sequence.
As described above, multiplex amplification of entity identification sequences and UEI-calibrators within droplets may be performed using any method known by the skilled person, preferably multiplex PCR. The amplification reaction mixture comprises all reagents required to perform DNA amplification into the droplets, i.e. typically a DNA polymerase, primers, buffers, dNTPs, salts (e.g. MgCl2), etc. . . . and primers are designed in order to allow the complete amplification of entity identification sequences and UEI calibrators.
Preferably, in embodiments producing chimeras between UEI and UEI-calibrator barcodes, in order to ensure a large over-representation of entity identification sequences and allow the proper barcoding of molecular targets after droplet fusion, the amplification reaction mixture comprises a higher amount of primers specific of the entity identification sequences relative to those specific for the UEI-calibrators. More preferably, the amplification reaction mixture comprises at least 5 times, preferably at least 10 times, and more preferably at least 100 times, higher amount of primers specific of the cell identification sequences relative to those specific for the UEI-calibrators.
In embodiments producing tripartite molecules comprising a labelled molecular target, an UEI sequence and a UEI-calibrator barcode, the amplification reaction mixture may comprise similar amounts of primers specific of the entity identification sequences and primers specific for the UEI-calibrators.
Optionally, UEI sequence and UEI-calibrators may be assembled through their compatible overhangs before amplification. In this case, amplification reaction therefore directly amplify a fragment comprising UEI sequence and UEI-calibrators. After fusion with the first set of droplets, said fragment is ligated to labelled molecular targets.
Droplet Fusion and Incorporation of UEI Barcodes, and Optionally UEI-Calibrator Barcodes, into Labelled Molecular Targets
As described above, the first set of emulsion droplets comprises molecular targets labelled with molecular identification sequence comprising UMI barcodes, and the second set of emulsion droplets comprises entity identification sequences comprising UEI barcodes, and optionally UEI calibrators.
The method of the invention comprises fusing droplets of the first set with droplets of the second set wherein a droplet of the first set is fused with no more than one droplet of the second set.
Any technique known by the skilled person may be used to fuse a first droplet and a second droplet together to create a combined droplet. For example, opposite electric charges may be given to the first and second droplets (i.e., positive and negative charges, not necessarily of the same magnitude), which may increase the electrical interaction of the two droplets such that fusion or coalescence of the droplets can occur due to their opposite electric charges. For instance, an electric field may be applied to the droplets, the droplets may be passed through a capacitor, a chemical reaction may cause the droplets to become charged, etc.
Any technique known by the skilled person may be used to ensure that a droplet of the first set is fused with no more than one droplet of the second set. In particular, droplets may be paired through a pairing channel before to reach the coalescence point. The use of such channel is well-known by the skilled person in order to control fusion of microfluidic droplets. In embodiments wherein a pairing channel is used, droplets of the first and second sets should have different sizes. The pairing channel is a long channel having a width larger than the smallest droplets and narrower than the largest droplets. As a consequence, the small droplet catches the large one and pairs of droplets are formed at the exit of the channel. This configuration ensures that droplets properly pairwise prior to reaching the coalescence point. An exemplary embodiment of such pairing channel is illustrated in
In some embodiments, droplets of the first set and/or droplets of the second sets are generated on separate microfluidic system(s) and re-injected into the device. Preferably, droplets are spaced with oil streams and synchronized before to enter the pairing channel.
Preferably at least 60%, more preferably at least 80% of droplets, and even more preferably at least 95% of the first set are fused with a droplet of the second set.
After droplet fusion, UEI barcodes are incorporated into labelled molecular targets through restriction enzyme digestion and ligation.
In embodiments wherein droplets of the second set do not comprise UEI calibrators, UEI barcodes are incorporated into labelled molecular targets through restriction enzyme digestion and ligation of the compatible overhangs of labelled molecular targets and digested entity identification sequences comprising UEI barcodes.
In embodiments wherein droplets of the second set comprise UEI calibrators and said UEI calibrators comprise a overhang producing restriction site, (i) UEI calibrator barcodes and UEI barcodes on one hand, and (ii) UEI barcodes and labelled molecular targets on the other hand, may be assembled through restriction enzyme digestion and ligation of compatible overhangs of (i) UEI calibrators and entity identification sequences and of (ii) entity identification sequences and labelled molecular targets. In this embodiment, entity identification sequences are appended to both the labelled molecular targets and the UEI-calibrators through a digestion/ligation coupled reaction. An exemplary illustration of such embodiment is presented in
In embodiments wherein droplets of the second set comprise UEI calibrators and said UEI calibrators comprise two overhang producing restriction sites, UEI calibrator barcodes, UEI barcodes and labelled molecular targets are assembled to through restriction enzyme digestion and ligation of compatible overhangs of (i) UEI calibrators and labelled molecular targets on one hand and (ii) UEI calibrators and entity identification sequences on the other hand. In this embodiment, the entity identification sequence, the UEI-calibrator and the labelled molecular target together form a tripartite molecule. An exemplary illustration of such embodiment is presented in
In an embodiment, restriction sites comprised on entity identification sequences and UEI calibrators are identical and only one restriction enzyme is used to digest entity identification sequences and UEI calibrators. In embodiments wherein molecular identification DNA sequences comprise a restriction site generating an overhang, this restriction site and restriction sites comprised on entity identification sequences and UEI calibrators may be identical or different, preferably different.
In another embodiment, restriction sites comprised on entity identification sequences and UEI calibrators are different and two different restriction enzymes are used to digest entity identification sequences and UEI calibrators. The use of different restriction sites and of labels with compatible extremities ensures that a productive ligation event leads to the destruction of the restriction site. Therefore, the resulting chimeric molecule will not be a substrate of the restriction enzymes present in the mixture and the equilibrium is pulled toward the formation of the wished ligation products. In embodiments wherein molecular identification DNA sequences comprise a restriction site generating an overhang, this restriction site may be identical or different of the restriction site comprised on entity identification sequences or on UEI calibrators. Preferably, this restriction site is identical to the restriction site comprised on UEI calibrators.
Preferably, these restriction sites are non-palindromic in order to ensure directionality of the association of cell identification sequences, UEI calibrators and labelled molecular targets.
In embodiments wherein UEI sequence and UEI-calibrators are assembled through their compatible overhangs before amplification, i.e. before fusion of the two sets of droplets, the fragment comprising UEI sequence and UEI-calibrators can be ligated to labelled molecular targets through compatible overhangs of i) UEI calibrators and labelled molecular targets or (ii) entity identification sequences and labelled molecular targets.
Restriction enzymes, DNA ligase and optionally buffer may be added to the droplets after droplet fusion, e.g. by pico-injection or droplet fusion, or concomitantly to droplet fusion, e.g. by injection at a T-junction (see e.g.
The emulsion may be then collected and incubated to allow digestion and ligation and thus association of UEI barcodes and labelled molecular targets, and UEI-calibrator barcodes when present.
In a particular embodiment wherein the molecular target is a nucleic acid, preferably a RNA, a sequencing primer annealing sequence may be added to labelled molecular target after incorporating UEI barcodes, and optionally UEI-calibrator barcodes. In particular, the method may further comprise, after incorporating UEI barcodes, and optionally UEI-calibrator barcodes, performing primer extension reaction using primers comprising from their 3′end to their 5′end, a region that hybridizes to complementary strands of molecular targets, i.e. to cDNA, and a sequencing primer annealing sequence.
Optionally, at their 5′ extremity, the primers may further comprise a binding tag allowing the specific capture of primer extension reaction products. Preferably, the binding tag is biotin or digoxigenin, more preferably is biotin.
Primer extension reaction may be performed as described above and reaction mixture may be brought into the droplet using any known method such as pico-injection or droplet fusion. Alternatively, the primer extension reaction can be performed in bulk upon droplet breaking and content recovery.
After completion of the labelling process, droplets may be broken and their content may be recovered, i.e. droplet lysate, e.g. to be further analysed/sequenced.
Analysis of Molecular Targets Labelled with the Method of the Invention
In a further aspect, the present invention also relates to a method of quantifying one or several molecular targets from a plurality of entities with single-entity resolution, said method comprising
labelling said molecular targets according to the method of the invention as described above, capturing said labelled molecular targets comprising UMI, UEI, and optionally UEI calibrator barcodes,
amplifying sequences comprising UMI and UEI barcodes, and optionally UEI-calibrator barcodes
sequencing said amplified sequences.
All embodiments described above for the method of the invention are also encompassed in this aspect.
The step of capturing labelled molecular target comprising UMI, UEI, and optionally UEI calibrator barcodes, allows removing from the droplet lysate untargeted molecules, unreacted entity identification sequences and/or UEI calibrators when present. This step may be performed using any capture molecule which is able to specifically bind molecular targets such as an antibody or nucleic acid specific of a molecular target, attached to a support. The capture molecule may be directly or indirectly attached to the support. In particular, the capture molecule may comprise a binding tag, e.g. biotin, interacting with a partner, e.g. streptavidin, linked to the support. The capture molecule may be for example a biotinylated monoclonal antibody specific of a targeted protein, or synthetic DNA oligonucleotide specific of a cDNA produced from a targeted RNA. A binding tag can be added during the synthesis of the second cDNA strand by primer extension mentioned above. The support may be chosen in order to allow washing of unreacted molecules. Preferably the support is beads, more preferably streptavidin conjugated beads. In some preferred embodiments, the support is magnetic beads, in particular streptavidin conjugated magnetic beads.
The nucleic acids comprising (i) the molecular identification DNA sequence comprising the UMI barcode and optionally the type identifier and (ii) the entity identification sequence comprising the UEI barcode are then sequenced using any method known by the skilled person, preferably using a next generation sequencing method.
In some embodiments wherein the entity identification sequence, the UEI-calibrator and the labelled molecular target together form a tripartite molecule, the nucleic acids to be sequenced comprise i) the molecular identification DNA sequence comprising the UMI barcode and optionally the type identifier, (ii) the entity identification sequence comprising the UEI barcode and (iii) the UEI-calibrator barcode.
In some other embodiments wherein the entity identification sequences are separately associated with UEI-calibrators and with molecular identification DNA sequence, the nucleic acids to be sequenced comprise (i) the molecular identification DNA sequence comprising the UMI barcode and optionally the type identifier and the entity identification sequence comprising the UEI barcode, and (ii) the entity identification sequence comprising the UEI barcode and the UEI-calibrator barcode.
In some embodiments, wherein said nucleic acids do not comprise any sequencing primer annealing sequences, said sequences may be added before the sequencing step, preferably by DNA amplification using primers comprising said sequences or by ligation of oligonucleotides comprising said sequences.
Preferably, when the molecular target is RNA, a part of this RNA is also sequenced.
One of the main advantage of the present invention is the possibility of pooling all captured labelled molecular targets prior to the sequencing step, whatever the type of molecular targets (e.g. RNA or protein). Sequences may be then analyzed using any method known by the skilled person such as bioinformatics to cluster said sequences and determining the absolute quantification of molecular targets. Firstly, UEI and UEI-calibrator barcodes are used to cluster the set of UEI labeling the molecules originating from the same entity. Secondly, UEI barcodes are used to cluster molecules according to their entity of origin. Third, molecules are clustered according to their type and identity, optionally using the type Identifiers, and, finally, redundant sequences are eliminated using the UMI barcodes giving access to the absolute quantification of each molecule with single-entity resolution.
Microfluidic Devices
In a further aspect, the present invention also relates to a microfluidic device suitable for implementing at least one step of the methods of the invention.
All embodiments described above for the methods of the invention are also encompassed in this aspect.
As used herein, the term “microfluidic device”, “microfluidic chip” or “microfluidic system” refers to a device, apparatus or system including at least one microfluidic channel.
The microfluidic system may be or comprise silicon-based chips and may be fabricated using a variety of techniques, including, but not limited to, hot embossing, molding of elastomers, injection molding, LIGA, soft lithography, silicon fabrication and related thin film processing techniques. Suitable materials for fabricating a microfluidic device include, but are not limited to, cyclic olefin copolymer (COC), polycarbonate, poly(dimethylsiloxane) (PDMS), poly(methyl methacrylate) (PMMA), and glass. Preferably, microfluidic devices are prepared by standard soft lithography techniques in PDMS and subsequent bonding to glass microscope slides. Due to the hydrophilic or hydrophobic nature of some materials, such as glass, which adsorbs some proteins and may inhibit certain biological processes, a passivating agent may be necessary. Suitable passivating agents are known in the art and include, but are not limited to silanes, fluorosilanes, parylene, n-dodecyl-β-D-maltoside (DDM), poloxamers such as Pluronics.
As used herein, the term “channel” refers to a feature on or in an article (e.g., a substrate) that at least partially directs the flow of a fluid. The term “microfluidic channel” refers to a channel having a cross-sectional dimension of less than 1 mm, typically less than 500 μm, 200 μm, 150 μm, 100 μm or 50 μm, and a ratio of length to largest cross-sectional dimension of at least 2:1, more typically at least 3:1, 5:1, 10:1 or more. It should be noted that the terms “microfluidic channel”, microchannel” and “channel” are used interchangeably in this description. The channel can have any cross-sectional shape (circular, oval, triangular, irregular, square or rectangular, or the like). Preferably, the channel has a square or rectangular cross-sectional shape. The channel can be, partially or entirely, covered or uncovered. As used herein, the term “cross-sectional dimension” of a channel is measured perpendicular to the direction of fluid flow.
The microfluidic device of the invention comprises
wherein emulsion re-injection modules and/or on-chip droplet generation modules are in fluid communication and upstream to the droplet-pairing module, the droplet-pairing module is in fluid communication and upstream to the module coupling droplet fusion to injection.
As used herein, the term “upstream” refers to components or modules in the direction opposite to the flow of fluids from a given reference point in a microfluidic system.
As used herein, the term “downstream” refers to components or modules in the direction of the flow of fluids from a given reference point in a microfluidic system.
In an embodiment, the microfluidic device of the invention comprises
two emulsion re-injection modules
a droplet-pairing module, and
a module coupling droplet fusion to injection.
An exemplary embodiment of such microfluidic device is presented in
In another embodiment, the microfluidic device of the invention comprises
an emulsion re-injection module and an on-chip droplet generation module,
a droplet-pairing module, and
a module coupling droplet fusion to injection.
In a further embodiment, the microfluidic device of the invention comprises
two on-chip droplet generation modules,
a droplet-pairing module, and
a module coupling droplet fusion to injection.
The emulsion re-injection module may be easily designed by the skilled person based on any known techniques. Typically, an emulsion re-injection module comprises a v-shaped structure where injected droplets are spaced by carrier oil supplying by at least one, preferably two side channels connected with the re-injection channel.
The module for generating droplets may be easily designed by the skilled person based on any known techniques. For example, emulsion droplets may be produced in the droplet generation module by any technique known by the skilled person such as drop-breakoff in co-flowing streams, cross-flowing streams in a T-shaped junction (see for example WO 2002/068104), and hydrodynamic flow-focussing (reviewed by Christopher and Anna, 2007, J. Phys. D: Appl. Phys. 40, R319-R336).
As explained above, the droplet-pairing module is a channel with dimensions allowing the contact between droplets of the two sets. In an embodiment, the width of the channel is about the diameter of the larger droplets and the depth of the channel is lower than the diameter of the larger droplets. In another embodiment, the depth of the channel is about the diameter of the larger droplets and the width of the channel is lower than the diameter of the larger droplets.
The length of the pairing channel has to be sufficient to obtain a contact between droplets of the first and second sets. Preferably, the time of contact is greater than 1 ms, preferably greater than 4 ms. As used herein, “the contact time τ” refers to the time in which paired droplets stay in physical contact before reaching the end of the pairing channel. Typically, the length of the pairing channel is ranging from 100 μm to 10 mm, preferably from 500 μm to 2 mm, and more preferably is about 1.5 mm.
The module coupling droplet fusion to injection is preferably a module wherein droplets, after pairing, are exposed to an electric field destabilizing their interface thanks to the proximity of electrodes, and are, in the same time, contacted with a stream injected in the channel. Destabilization of the interface then leads not only to droplet coalescence but also to infusion of the injected stream into droplets.
The microfluidic device may further comprise a collection module wherein fused droplets are recovered.
Optionally, the microfluidic device of the invention may comprise an inlet downstream to the module coupling droplet fusion to injection and upstream to the collection module. This inlet may be used to inject additional surfactant in order to increase the stability of fused droplets and to prevent any coalescence during the storage.
In another aspect, the present invention also relates to a kit comprising a microfluidic device according to the invention and as described above.
The kit may further comprise one or several microfluidic chips comprising an on-chip droplet generation module.
The kit of the invention may further comprise
All embodiments described above for the methods and the microfluidic device of the invention are also encompassed in this aspect.
In another aspect, the present invention also to a kit comprising
All embodiments described above for the methods and the microfluidic device of the invention are also encompassed in this aspect.
The present invention further relates to the use of a kit of the invention to label a plurality of molecular targets from a plurality of entities according to the method of the invention, or to quantify one or several molecular targets from a plurality of entities according to the method of the invention. All embodiments described above for the methods, the microfluidic device and the kit of the invention are also encompassed in this aspect.
As used herein, the verb “to comprise” is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”.
As used herein, the term “about” refers to a range of values ±10% of the specified value. For example, “about 20” includes ±10% of 20, or from 18 to 22. Preferably, the term “about” refers to a range of values ±5% of the specified value.
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
I. Microfluidics Chips Fabrication and Operation
In all the examples presented below microfluidic chips were fabricated using the same procedure and they were manipulated using on the same workstation.
a. Microfluidic Chips Preparation and Operation
Microfluidic devices were obtained using a classic replica molding process as described previously in (Mazutis et al., 2009). Briefly, devices were designed on Autocad (Autodesk 2014), negative photomasks were printed (Selba S. A.) and used to prepare molds by standard photolithography methods. SU8-2010 and SU8-2025 photoresist (MicroChem Corp.) were used to pattern 10 to 40 μm deep channels onto silicon wafers (Siltronix). Microfluidic devices were then fabricated in polydimethylsiloxane (PDMS, Silgard 184, Dow-Corning) using conventional soft lithography methods (Xia and Whitesides, 1998). Upon plasma bonding to a glass slide, channels were passivated with a solution of 1% (v/v) 1H, 1H, 2H, 2H-perfluorodecyltrichlorosilane (97%, ABCR GmbH and Co) in HFE7500 (3M) and subsequently flushed with compressed air. Key dimensions and depth of microfluidic devices are given on concerned figures and in their captions.
Aqueous phases were loaded in I.D. 0.75 mm PTFE tubings (Thermo Scientifc) and oils were loaded in 2 mL Micrew Tubes (Thermo Scientific). Liquids were injected into microfluidic devices at constant and highly controlled flow-rates using a 7-bar MFCS™ pressure-driven flow controller (Fluigent) equipped with Flowells (7 μL/min flow-meters) allowing for operation in flow-rate controlled mode.
b. Optical Set-Up, Data Acquisition and Control System
The optical setup was based on an inverted microscope (Nikon Eclipse Ti-S) mounted on a vibration-dampening platform (Thorlabs B75150AE). The beams of a 488 nm laser (CrystaLaser DL488-050-0) and a 561 nm laser (Cobolt DPL 561-NM-100MW) were combined using a dichroic mirror (Semrock 2F495-DI03-2536). They were further combined with a 375 nm laser (CrystaLaser DL375-020-0) using a second dichroic mirror (Semrock Di02-R405-25×36) prior to shaping the resulting combined beam as lines using a pair of lenses (Semrock LJ1878L2-A and 111567L1-A) that was directed into the microscope objective (Nikon Super Plan Fluor 20× ELWD or Nikon Super Plan Fluor 40× ELWD) to be focused in the middle of the channel at the detection point. The emitted fluorescence was collected by the same objective and separated from the laser beams by a multi-edges dichroic mirror (Semrock Di01-R405/488/561/635-25×36). Blue (7-amino coumarin-4-methanesulfonic acid) fluorescence was resolved from green (Syto9, FAM) and orange (Texas-Red) fluorescence by a third dichroic mirror (Semrock LM01-480-25). Then green fluorescence was separated from orange fluorescence by an additional dichroic mirror (Semrock FF562-Di03-25×36). Fluorescence was finally measured by three photomultiplier tubes (Hamamatsu H10722-20) equipped with bandpass filters (Semrock FF01-445/45-25, FF01-600/37-25 and FF03-525/50-25 for blue, green and orange detection respectively). Signal acquisition from the PMTs was performed using an intelligent data acquisition (DAQ) module featuring a user-programmable FPGA chip (National Instruments PCI-7851R) driven by internally developed firmware and software. To monitor the experiment, we used an additional dichroic mirror (Semrock FF665-Di02-25×36) to split light to a CCD camera (Allied Vision Technologies Guppy F-033). A long-pass filter (Semrock BLP01-664R-25) prevented potentially damaging reflections of the lasers into the camera.
II. Sequences Used in the Examples
NNNNNNNNNNNNNNNNNN
CAGGGGCTGGTCGTGACTGGGAAAAC
NNNGATCGGAAGAGCGTCGTGT
NNNNNNNNNNNNN
CAGGGGCTGGTCGTGACTGGGAAAACCCTGGC
NNNNTTGGCTGTCTCTTATACACATCTGACGCTGCCGACGA
NNNGATCGGAAGAGCGTCGTGTCTGTCTCTTATACACATCTCCGAGC
In this example, we demonstrated that bacterial cells can be individualized in droplets and efficiently lysed using a detergent. E. coli bacteria (T7-Xpress Lys/Iq, GFP null strain New England Biolabs) transformed either with a plasmid carrying GFP gene under the control of T7 RNA polymerase promoter or a plasmid bearing an unrelated construct were used as model bacteria and will be later summarized as strains GFP+ and GFP-respectively. Note that both plasmids confer ampicillin resistance to the bacteria allowing for their co-culture.
a. Preparation of the Cell
A cell pre-culture (starter) was first obtained by inoculating a 2YT media supplemented with 0.1 mg/mL ampicillin and 2% glucose, and incubating it over-night at 37° C. and under agitation. 500 μl of this starter (OD600 of 3.77) were then used to inoculate 20 mL of the same medium, and the bacteria were allowed to grow until the culture reached an OD600 of 0.6. Next, the cells were fluorescently stained to allow for monitoring cells during the microfluidic steps. To do so, 2 mL of this culture were stained using 5 μM SYTO 9 (molecular probes by Life technologies, ref 34854) for 2 hours in the dark, following supplier recommendations. Cells were washed once with PBS buffer 1× before being pelleted for further experiments.
b. Cells Encapsulation and Lysis
Experimental Procedure
Pellets of labelled cells were diluted to reach an OD600 of 3.75 (giving a droplet occupancy of −20%) in a CutSmart® buffer 1× (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA, New England Biolabs) supplemented with 37.5 μg/mL dextran Texas red 70 000 MW (used as droplet tracker), and 0.05% Pluronic F68. The mixture was then loaded into a 0.5 mL PCR tube containing a magnetic stirring bar (5 mm length and 2 mm diameter) closed by a plug of PDMS. One extremity of the system was connected to a Fluigent infusion device whereas the other extremity was connected to the droplet co-flow generator (
In this example, we show how Unique Identifiers (UIs) can be prepared both in bulk and in microfluidic droplets as well as how they can be used to generate a signature encoding droplet identity. A UI is made of a pair of random sequences (the UEI (“unique entity identifier”) and the UEI Calibrator) surrounded by constant sequence regions encompassing restriction sites generating compatible extremities later used to recombine both sequences together (
a. Duplex PCR Co-Amplification of the Two Barcode Sets
We first validated the possibility of performing a duplex PCR co-amplification of UEI-Calibrator and UEI sequences in tubes prior to transferring it in droplet microfluidic format.
Experimental Procedure
500 atto moles of one or both templates (i.e. UEI-DraIII (1) and AlwNI-Calibrator-DraIII (4)) diluted into 0.2 mg/mL yeast total RNA (Ambion) were introduced into a reaction mixture containing 0.2 μM of each forward (molecules 2 and 6) and reverse (molecules 3 and 5) primers, 0.2 mM of each dNTP, 0.1% Pluronic F68, 0.67 mg/mL dextran Texas Red (Invitrogen), 6 nM of a Taq polymerase produced in the laboratory and 1× CutSmart® buffer (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA) in a final volume of 50 μL. The mixture was then thermocycled with an initial denaturation step of 30 sec at 95° C. followed by 25 cycles of 5 sec at 95° C. and 30 sec at 65° C.
Results
Upon amplification, PCR products with the expected size (62 base pairs for UEI-DraIII and 142 base pairs for AlwNI-Calibrator-DraIII) were readily observed on 8% polyacrylamide native gel. Whereas, a single band was observed when only one of the template was present (
b. Amplification of the PCR in Water-in-Oil Droplet
We next verified that the co-amplification can efficiently occur in droplets.
Experimental Procedure
14 atto moles (a concentration allowing for having a theoretical average of 4 template DNA molecules per droplet) of each template (i.e. Template UEI-N15-DraIII (7) and Template AlwNI-N15-Calibrator-DraIII (8)) diluted into 0.2 mg/mL yeast total RNA (Ambion) were introduced in 200 μL of reaction mixture containing 0.2 μM of each forward (molecules 2 and 6) and reverse (molecules 3 and 5) primers, 0.2 mM of each dNTP, 0.1% Pluronic F68, 0.67 mg/mL dextran Texas Red (Invitrogen), 6 nM of a Taq polymerase produced in the laboratory and 1× CutSmart® buffer (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA. The mixture was then loaded into a length of PTFE tubing (I.D. 0.75 mm tubing; Thermo Scientifc) and connected to the Fluigent infusion device at one side of the tubing while the other the other side was connected to a 40 μm deep droplet generator (
Results
Gel analysis confirmed that the duplex PCR amplification properly worked in water-in-oil droplets (
c. UI-Based Signature
Forming the UI requires recombining together the UEI-Calibrator and the UEI through a restriction/ligation coupled reaction. To do so, we choose two non-palindromic restriction sites producing compatible 3′ overhangs. AlwNI (5′-CAGNNN/CTG-3′) and DraIII (5′-CACNNN/GTG-3′) are two enzymes digesting sequences (bolded in Table 1) fulfilling these criteria. Digestion at these sites generates two compatible sequences that can recombine together and form new sequences (i.e. 5′-CAGNNNGTG-3′ and 5′-CACNNNCTG-3′) that can no longer be digested by the enzymes, pulling therefore the equilibrium toward the formation of recombined molecules.
Experimental Procedure
The duplex PCR established in section b was repeated using template molecules 7 and 8 and amplification primers 3, 5 and 6. However, primer 2 was exchanged for primer 9 that allowed introducing Illu-1 sequence, an adaptor sequence later used for next generation sequencing analysis. To evaluate to what extend the relative amount of both barcodes can affect recombination efficiency, so UI formation, we performed a set of experiments using two relative concentrations of UEI-Calibrators and UEI in the droplets. This ratio was changed by varying the concentration of the corresponding primers in the PCR mixture. However, the diversity of the barcodes was preserved by initiating each experiment with the same average number of template per PCR droplet. Therefore, in a first reaction set 14 atto moles of each template diluted into 0.2 mg/mL yeast total RNA (Ambion) were mixed with 0.2 μM of each primer (3, 5, 6 and 10) giving a final ratio UEI-Calibrator/UEI of 1/1. In a second set of reactions, 14 atto moles of each template diluted into 0.2 mg/mL yeast total RNA (Ambion) were mixed with 0.2 μM of primers 3 and 10 and 0.02 μM of primers 5 and 6, giving a final ratio UEI-Calibrator/UEI of 0.1/1. Each template/primers mixture was then introduced into 200 μL of reaction mixture containing 0.2 mM of each dNTP, 0.1% Pluronic F68, 0.67 mg/mL dextran Texas Red (Invitrogen), 6 nM of a Taq polymerase produced in the laboratory and 1× CutSmart® buffer (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA). The mixture was dispersed into 100 pL droplets as above and the emulsion was collected for 20 min in a 0.2 mL tube closed by a plug of PDMS and thermocycled as before. Upon thermocycling, the emulsion was reinjected into a droplet picoinjector (
Finally, the sequences were analyzed using a Python-based bioinformatics algorithm (
Results
The UI signature readily forms only in the presence of restriction/ligation enzymes. Indeed, the qPCR analysis revealed that whatever the UEI-Calibrator/UEI ratio used, more than 10 additional amplification cycles (delta Ct >10) are required the reach the threshold in the absence of recombination enzymes (
Further analyzing the droplet-contained UI by Next Generation Sequencing together with the bioinformatics algorithm shown on
Clustering the different UIs contained in each droplet allows obtaining a signature unique to each droplet. Interestingly, the signatures were evenly represented within the pool of sequences (
d. Adjusting UEI Diversity
To further confirm that both UEI-Calibrators and UEIs distributes into the droplets following a Poisson distribution, as well as to properly adjust the content of each type of barcodes, the experiment was performed at three different average number (lambda values) of barcode per droplet.
Experimental Procedure
As before, a duplex PCR was performed but using different starting amount of template molecules 7 and 8. To test the lambda 1.3 condition (i.e. an average of 1.3 UEI-Calibrator and 1.3 UEI per droplet), 5 atto moles of each template (i.e. Template UEI-N15-DraIII (7) and Template AlwNI-N15-Calibrator-DraIII (8)) diluted into 0.2 mg/mL yeast total RNA (Ambion) were introduced into 200 μL of a reaction mixture containing 0.2 μM of each forward (molecules 2 and 6) and reverse (molecules 3 and 5) primers, 0.2 mM of each dNTP, 0.1% Pluronic F68, 0.67 mg/mL dextran Texas Red (Invitrogen), 6 nM of a Taq polymerase produced in the laboratory and 1× CutSmart® buffer (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA. To test the lambda 4 (i.e. an average of 4 different UEI-Calibrators and 4 different UEIs per droplet) and lambda 12 (i.e. an average of 12 different UEI-Calibrators and 12 different UEIs per droplet) conditions, the starting amount of each template introduced in the reaction mixture was respectively raised to 14 atto moles and 56 atto moles. 100 pL droplets were generated at a frequency of 300 droplets per second using the same chip as before (
Results
Preparing UIs in droplets while varying the initial number of UEI-Calibrator and UEI template per droplet (lambda value) did not significantly challenged the process per se. Indeed, whatever the starting lambda value (from 1.3 to 12), very close Ct values were obtained when quantifying the amount of DNA amplified and recombined into the droplets at the of the process (reactions 2 to 3 on
Analyzing the sequence content of an aliquot of 1000 droplets from each condition with our bioinformatics algorithm revealed that, as expected, changing the starting amount of UEI-Calibrator and UEI template per droplet directly impacts the distribution of both barcodes in the droplets (
Since UIs are obtained through a digestion/ligation process, they can also be appended to another DNA molecule provided it possesses a site compatible with one of the restriction products. This DNA could be either a reverse transcription product or a DNA attached to another molecule such as a protein. In this example, we demonstrate the possibility of attaching UI to another DNA and to later use our approach to reassign each DNA molecule to the droplet it originates from as well as quantifying the DNA content of each droplet. Therefore, in this example we aimed to: i) isolate and PCR co-amplify UEI-Calibrator and UEI templates; ii) supplement each UEI-Calibrator/UEI-containing droplet with a DNA displaying an extremity compatible with one of the restriction products; iii) add restriction/ligation enzymes to each droplet to form UIs through recombination and attach them at the extremity of the target DNA molecule; iv) index and sequence the library in high throughput regimes. Furthermore, a random sequence of 8 nucleotides forming a Unique Molecular Identifier (UMI) was inserted into the target DNA to allow the later counting of the molecules contained in each droplet.
a. UEI Formation and DNA Labeling in Tubes
Prior to performing DNA labelling in droplets, we first verified the whole reaction process in tubes. In this example, we used a partially double stranded DNA mimicking a reverse transcription product (
Experimental Procedure
UI components (UEI-Calibrators and UEIs) were first generated as in Example 2 by a duplex PCR co-amplification. To do so, 500 atto moles of template DNAs 7 and 11 were first PCR amplified in a volume of 200 μL as described in Example 2 section a using 0.2 μM of primers 2, 3, 5 and 12. Target DNA was prepared by annealing together 1.25 μmol of the molecule 13 and 1.25 μmol of the molecule 14 in 20 μL of 1× CutSmart® buffer, 0.25 mM dNTP, 10 mM DTT, 0.1 μM FAM, 0.15 mg/mL dextran Texas Red. The enzyme mixture was prepared by supplementing a 1× CutSmart® buffer with 6 mM rATP, 60 mM DTT, 8 U/μL DraIII HF, 8 U/μL AlwN1, 80 U/μL T4 DNA ligase, 55 μM coumarin acetic and 0.3% Pluronic F68. 10 μl of duplex PCR were then mixed with 4 μL of target DNA solution and 3 μL of Enzyme mixture and the resulting mixture was incubated overnight at 37° C. As a control, the same reaction was performed but restriction enzymes and the ligase were omitted from the enzyme mixture. Upon incubation, an aliquot of each reaction was analyzed by quantitative PCR using the kit Sso-Fast Evagreen (Bio-Rad) supplemented in primers 3 and 6. After the qPCR, an aliquot of each reaction was analyzed on polyacrylamide gel electrophoresis.
Results
The annealing of molecule 13 and 14 form a target DNA displaying a 3′ overhang compatible with the DraIII product generated upon UEI-Calibrator digestion. Mixing together this target DNA with co-amplified UEI-Calibrators and UEIs as well as with restriction and ligation enzymes allows the formation of UIs and their attachment to the target DNA, therefore directly encoding it. qPCR analysis indicates that more than 17 additional amplification cycles (delta Ct >17) are required the reach the threshold in the absence of recombination enzymes (
Therefore, UIs can be used to encode a DNA displaying an overhang compatible with one of the restriction site present in the UI.
b. UI Formation and DNA Labeling in Droplet
We next transposed the DNA labelling into the droplet microfluidic format. As in Example 2, UEI-Calibrators and UEIs were co-amplified in droplets using a duplex PCR prior to adding the DNA to label and the enzyme mixture to each droplet.
Experimental Procedure
An extended version of the molecule 7 encompassing the sequencing adapter Illu1 was first prepared by primer extension. Briefly, 10 μmols of the template 7 were mixed with 50 μmols of primer 9 in a 50 μL reaction mixture containing 0.2 mM of each dNTP, 1U of Phusion DNA polymerase (ThermoScientific) and the corresponding buffer at the recommended working concentration. The mixture was then incubated for 5 minutes at 98° C. and 10 minutes at 72° C. Extension product was then purified on an agarose gel and the DNA recovered with the Wizard SV Gel and PCR clean up system (Promega). The extended molecule is now called Template UEI-N15-DraIII-Illu1 and corresponds to molecule 15. 14 atto moles (a concentration allowing for having an average of 4 template DNA molecules per droplet) of each template (i.e. Template UEI-N15-DraIII-Illu1 (15) and Template-AlwNI-N15-Calib-DraIII (11)) diluted into 0.2 mg/mL yeast total RNA (Ambion) were introduced into a reaction mixture containing 0.2 μM of each forward (molecules 2 and 5) and reverse (molecules 10 and 12) primers, 0.2 mM of each dNTP, 0.1% Pluronic F68, 0.67 mg/mL dextran Texas Red (Invitrogen), 6 nM of a Taq polymerase produced in the laboratory and 1× CutSmart® buffer (50 mM Potassium acetate, 20 mM Tris acetate pH7.9 at 25° C., 10 mM Magnesium acetate and 0.1 mg/mL BSA) in a final volume of 200 μL. The mixture was then loaded into a length of PTFE tubing (I.D. 0.75 mm tubing; Thermo Scientifc) and connected to the Fluigent infusion device at one side of the tubing while the other the other side was connected to a 40 μm deep droplet generator (
Results
In this example, we prepared an emulsion made of 20 pL droplets, each containing on average ˜1000 target DNA molecules. In parallel, UEI-Calibrator/UEI-containing droplets were prepared as described in Example 2. Finally, using our Barcoding microfluidic device (
Since our methodology allows for labelling and counting the DNA molecule contained into the droplets of an emulsion, we next investigated if RNA can be converted, in the droplets, into a cDNA that could be used as a substrate of our labelling technology. To generate such cDNA, we designed composite reverse transcription (RT) primers made of i) double-stranded 5′ part terminated by a 3′ overhang compatible with the restriction site present at the extremity of the UI; followed by ii) a single-stranded region containing 8 random nucleotides and working as Unique Molecular Identifier (UMI) and iii) terminated by 3′ single-stranded region annealing specifically to the target RNA (
a. Reverse Transcription of RNAs in Droplets
To test the possibility of reverse transcribing RNAs in the droplets, we choose the highly structured (therefore challenging to reverse transcribe) RNA III from Staphylococcus aureus (Benito et al, 2000). The RNA was prepared by in vitro transcription using T7 RNA polymerase using the same procedure described in (Ryckelynck et al, 2015). Upon transcription, RNA was purified on a size exclusion column Nap5 (GE-Healthcare) and quantified using a Nanodrop device. To prevent unwanted reverse transcription of the RNA prior to its encapsulation in droplets, RNA and RT reagents were first emulsified separately and mixed together through droplet fusion (Mazutis et al, 2009). Moreover, to evaluate the sensitivity of the reverse transcription process, we prepared emulsions containing 10, 100 or 1000 RNA molecules per droplet. Then the reverse transcription was added to each droplet and the RT allowed to proceed prior to analyzing the produced cDNA.
Experimental Procedure
0.6, 6 or 60 femto moles of RNA-III (allowing for having respectively, 10, 100 or 1000 RNA molecule per 2 pL droplet) were introduced into a 100 μL of a solution containing CutSmart® buffer, 1.5 mg/mL Dextran Texas Red (Invitrogen), 0.25% Pluronic F68. The mixture was then loaded into a length of PTFE tubing (I.D. 0.75 mm tubing; Thermo Scientifc) and connected to the Fluigent infusion device at one side of the tubing while the other the other side was connected to a 10 μm deep droplet generator (
Results
In this example, emulsions of 2 pL droplets containing each 10, 100 or 1000 molecules of RNA-III were produced and fused to 18 pL droplets containing an RT mixture. As a control, the same experiment was performed in a bulk format. Upon incubation, qPCR analysis revealed that RT occurred with the same efficiency both in bulk and emulsified format (
We noticed that, when working at low concentration of target molecules, some non-specific recombination events occur between some primers and the randomized regions of the UEI-Calibrators and the UEIs. We therefore explored alternative sequences to the simple stretch of 15 contiguous randomized nucleotides. In this example, we reverse transcribed a purified gfp mRNA prior to subjecting the obtained cDNA the labeling by UI produced from templates: i) deprived of randomized regions; ii) or bearing a stretch of 15 contiguous randomized nucleotides (N15); iii) or bearing a stretch of semi-randomized nucleotides where 5 randomized dinucleotides are spaced by constant dinucleotides (N2×5); iv) or bearing a stretch of semi-randomized nucleotides where 4 randomized trinucleotides are spaced by constant trinucleotides (N4443).
Reverse Transcription of the GFP RNA and UI Addition
Experimental Procedure
gfp mRNA was prepared by in vitro transcription using T7 RNA polymerase using the same procedure described in (Ryckelynck et al, 2015). Upon transcription, RNA was purified on a size exclusion column Nap5 (GE-Healthcare) and quantified using a Nanodrop device. 16.67 femto moles of purified gfp mRNA were reverse transcribed in 20 μL CutSmart® buffer prepared at the recommended concentration and supplemented with 1.25 μmol of RT primer (molecule 23), 1.25 μmol of the complementary oligonucleotide (molecule 24), 1 mM dNTP, 10 mM DTT, 10 U of AMV reverse transcriptase, 0.1 μM FAM. The mixture was then incubated 1 hour at 42° C. 500 atto moles of pairs of template UEI-Calibrators and UEIs (i.e. 1/27, 25/28, 26/29 and 7/30) were co-amplified in 200 μL of amplification mixture supplemented with 0.2 μM of each primer (2, 5, 10 and 12) as described in Example 3-section a. Upon thermocycling, 10 μL duplex PCR were mixed with 4 μL of reverse transcribed reaction and 3 μL of Enzyme mixture (lx CutSmart® buffer with 6 mM rATP, 60 mM DTT, 8 U/μL DraIII HF, 8 U/μL AlwN1, 80 U/μL T4 DNA ligase, 55 μM coumarin acetic and 0.3% pluronic F68). The mixture was then subjected to 5 cycles of temperature: 15 min at 37° C. and 45 min at 16° C. At the end of the incubation, 1 μL of each reaction was amplified by PCR using the kit Sso-Fast Evagreen (Bio-Rad) supplemented in primers 3 and 6 and the amplification products were analyzed on a 1% agarose gel (
Results & Conclusions
The target RNA (gfp mRNA) was properly reversed transcribed and the 4 types of barcodes (UEI-Calibrator/UEI) were appended to the resulting cDNA. Whereas barcodes deprived of randomized regions or affording N2×5 semi-randomized regions gave homogeneous PCR products (lanes 1 and 2 on
To extend the use of the technology to molecules other than nucleic acids, we validated in this example the capacity of our method to encode a DNA fragment covalently attached to a protein. To this end, we cloned a fusion gene made of protein A and SNAP tag (New England Biolabs) coding regions. The resulting gene was overexpressed in E. coli and the resulting protein (NaBAb) was purified. In this example, we first verified that a unique fragment of DNA could be covalently attached to the protein and that it did not interfere with the capacity of the protein to interact with antibodies via its protein A moiety. Then, we tested if a UI could be attached to the DNA strand appended to the protein.
a. Labeling Antibodies with a Single DNA Per Antibody
We prepared a construct in which the sequence coding for the protein A was placed in fusion with a His-tagged version of the SNAP-tag (New England Biolabs) and placed the construct on an expression plasmid. The corresponding protein was then overproduced in E. coli and purified by affinity chromatography. The SNAP domain is a catalytic module reacting with benzyl-guanine-displaying substrate molecules. Upon reaction, a single molecule of substrate is covalently and irreversibly attached to the SNAP module (
Experimental Procedure
A template DNA (molecule 31) possessing a unique AlwNI as well as a UMI of 8 randomized positions was PCR amplified using a primer modified with a benzyl-guanine (BG) group (molecule 32) allowing for grafting the DNA on the SNAP module of NaBAb and a primer modified with an Alexa-488 fluorescent group (molecule 33) to fluorescently label the DNA. 10 μmols of template 31 were mixed with 1 nmol of each primer (32 and 33) in 1 mL of PCR solution containing 0.2 mM of each dNTP, 20 U of Q5 DNA polymerase (New England Biolabs) and the corresponding buffer at the recommended concentration. The mixture was then placed in thermocycler and subjected to an initial denaturation step of 30 sec at 98° C. followed by 25 cycles of 10 sec at 98° C., 10 sec at 55° C. and 30 sec at 72° C. Finally, the program was concluded by a final extension step of 2 min at 72° C. Amplification products were the purified using the kit Wizard SV Gel and PCR clean up system (Promega) and quantified with a Nanodrop device. 200 μmols of BG/Alexa488 dually labelled DNA were then mixed with 180 μmol of purified NaBAb in 1 mL of CutSmart® buffer (New England Biolabs) diluted at the recommended concentration (lx) and supplemented with 1 mM DTT. The same experiment in which NaBAb was omitted was performed in parallel and used as control. The mixture was incubated for an hour at 37° C. and an aliquot was analyzed on polyacrylamide gel electrophoresis and Alexa488 fluorescence revealed (
In a second experiment, 27 μmols of purified NaBAb were mixed with 20 μmols of BG/Alexa488 dually labelled DNA in 40 μL of CutSmart® buffer (New England Biolabs) diluted at the recommended concentration (1×) and supplemented with 1 mM DTT. Moreover, the mixture was also supplemented with 225, 112, 62.5 μg/mL of total Human IgG (Sigma Aldrich). Reactions in which IgG and/or the dually labelled DNA were omitted were used as control. The mixture was incubated for an hour at 37° C. and an aliquot was analyzed on polyacrylamide gel electrophoresis and Alexa488 fluorescence revealed (
Results & Conclusions
Incubating BG/Alexa488 dually labelled DNA with a slight excess of NaBAb allowed grafting all the DNA onto the SNAP module of NaBAb as attested by the complete up-shift of the DNA band on the gel (
b. Labelling NaBAb-DNA Complex with UEIs
We investigated the possibility of labelling the NaBAb-DNA complex by UIs using the labelling strategy presented in Example 3.
Experimental Procedure
500 atto moles of template UEI-Calibrators and UEIs (molecules 11 and 15) were co-amplified in 200 μl of PCR mixture supplemented with 0.2 μM of each primer (2, 5, 10 and 12) as described in Example 3-section a. Upon thermocycling, 10 μL duplex PCR were added to 10 μL of CutSmart® buffer (New England Biolabs) diluted at the recommended concentration (1×) supplemented with 2 μmol of NaBAb-DNA complex (prepared as described in section a of this Example), 2 mM rATP, 20 mM DTT, 2.5 DraIII HF (New England Biolabs), 2.5 U/μL AlwN1 (New England Biolabs), 25 U/μL T4 DNA ligase (New England Biolabs), 10 μM coumarin acetic and 0.1% pluronic F68. The mixture was then subjected to 5 cycles of temperature: 15 min at 37° C. and 45 min at 16° C. In parallel, we performed a control reaction in which restriction/ligation enzymes were omitted. At the end of the incubation, 1 μL of each reaction was analyzed by quantitative PCR using the kit Sso-Fast Evagreen (Bio-Rad) supplemented in primers 6 and 10, and the amplification products were analyzed on a 1% agarose gel (
Results & Conclusions
In this section, we showed that a DNA covalently associated to the NaBAb protein can serve as UI acceptor using or restriction/ligation strategy. Indeed, in absence of the enzymes more than 26 additional amplification cycles (delta Ct >26) were required the reach the threshold (
In conclusion, in this example, we demonstrated that the NaBAb fusion protein can be used to specifically label IgG with a unique DNA molecule and that, even though it is covalently attached to the NaBAb protein, this DNA can further serve as UI acceptor using our restriction/ligation strategy. Moreover, since the recombination occurs in native conditions preserving the association of non-covalent complexes (e.g. antibody/antigen), the combined use of NaBAb-DNA/IgG complex and of UI encoding can be used to label and encoded IgG-recognized targets (e.g. protein) and quantify them by Next Generation sequencing (e.g. MiSeq).
The different examples reported here demonstrate the complete technical feasibility of the method of the invention. Indeed, we demonstrated that the two components (the UEI-Calibrator and the UEI) of Unique Identifiers (UIs) can be efficiently co-amplified in a duplex PCR prior to being recombined together by restriction/ligation reactions to form UIs both in bulk (Example 2.a) and emulsified reactions (Example 2.b). The pool of UI contained in droplet can then be used as signature allowing for unambiguously assigning the sequences contained in a pool of Next Generation Sequencing data to the droplet they originate from (Example 2.c). Moreover, changing the initial number of different template UEI-Calibrators and UEIs was shown to allow adjusting the complexity of the signature (Example 2.d).
In addition, we demonstrated that these UI can be further attached to a target DNA molecule displaying a 3′ overhang compatible with a restriction site present on the UI both in bulk (Example 3.a) and in droplets (Example 3.b). Again, the use UI-based signature allowed to unambiguously assign each DNA sequence to the droplet it originated with a great droplet-to-droplet reproducibility.
Moreover, we showed that RNA can be efficiently reverse transcribed into cDNA in droplet (Example 4.a) using reverse transcription primers either competent for being later coupled with an UI (Example 4.b) or conjugated to an UI prior to being used for reverse transcribing the target RNA (Example 5). In both cases, similar yield of RT and UI coupling were obtained. Our encoding strategy is not limited to nucleic acids since we showed that our UI grafting strategy can also be applied to IgG labeled with a single DNA molecule possessing a restriction site making it compatible with our restriction/ligation approach (Example 6). This last scenario makes possible to encode non-nucleic acids targets such as proteins in a way that preserve non-covalent biological complexes (e.g. antibody/antigen complexes).
Finally, we showed that cells can be isolated and lysed into small 4 pL droplets (Example 1). Not only the material can be released from the cells, but the size of the droplets makes the directly compatible with the use of the droplet fusion device (
| Number | Date | Country | Kind |
|---|---|---|---|
| 16306543.6 | Nov 2016 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2017/080264 | 11/23/2017 | WO | 00 |
